TOM SOLOMON, ADJANIE PATABENDIGE, AND RICHARD J. WHITLEY
Conventionally, viruses are placed within families and genera according to the taxonomic system, based on morphologic, biochemical, antigenic, and genetic similarities. However, because the taxonomic system tells us nothing about how a virus is transmitted or about the patterns of disease it causes, it is of relatively little help to the practicing clinician. For this reason, alternative groupings that incorporate these clinical and epidemiologic aspects are often used. One such group is the arthropod-borne viral (or arboviral) encephalitides that includes viruses transmitted by arthropods (insect, ticks, sandflies, and biting midges) that are important causes of central nervous system (CNS) disease in humans. Altogether, there are more than 500 arthropod-borne viruses, or “arboviruses,” that come from four viral families (Togaviridae, Flaviviridae, Bunyaviridae, and Reoviridae); only a relatively small number of these viruses are responsible for human disease (Table 15.1). Within the family Togaviridae, the Alphavirus genus contains eastern, western, and Venezuelan equine encephalitis (EEE, WEE, and VEE) viruses—important causes of disease in horses and humans in the Americas—and chikungunya virus (CHIKV), which caused major outbreaks associated with severe morbidity in the Indian Ocean islands and in India during 2005 to 2007 (1). The flaviviruses (genus Flavivirus, family Flaviviridae) include Japanese encephalitis virus (JEV), which occurs across much of southern and eastern Asia and is the most important cause of epidemic encephalitis worldwide; West Nile virus (WNV), which has spread to cause large encephalitis outbreaks in the United States; dengue virus (DENV), which continue to be a global threat with over 100 million infected annually; and tick-borne encephalitis (TBE) viruses—important in Europe and Russia. Within the family Bunyaviridae, the Bunyavirus genus includes La Crosse virus (LACV) and other California serogroup viruses that cause encephalitis, whereas the Phlebovirus genus includes Toscana virus (TOSV), an important emerging cause of CNS disease in southern Europe. The Reoviridae family includes Colorado tick fever virus (CTFV) and similar members of the Coltivirusgenus that causes febrile illness and CNS disease.
Arboviruses classically cause three disease patterns in humans (Fig. 15.1): fever-arthralgia-rash syndromes, viral hemorrhagic fevers (often associated with hepatitis), and neurologic disease, which are the focus of this chapter. They constitute some of the most important emerging and reemerging infectious diseases. General principles of arboviral ecology, epidemiology, and pathogenesis, as well as diagnosis, management, and prevention of arboviral encephalitis, are discussed before the more important diseases are considered in more detail.
ECOLOGY OF ARBOVIRUSES
A basic understanding of the ecology of arboviruses is helpful in understanding the epidemiology of human disease. For most of the arboviruses that cause neurologic disease in humans, including many of the flaviviruses, alphaviruses, and bunyaviruses, humans are not part of the natural cycle, being incidental hosts (Fig. 15.2). In nature, these viruses are typically transmitted between birds or small rodents in enzootic cycles that use mosquitoes or ticks as vectors. To be evolutionarily successful, arboviruses require immunologically naive hosts, which is why most have evolved to use rapidly reproducing animals. Humans are infected when they encroach upon this natural enzootic cycle and are bitten by the vector. This may be because they live in or have entered areas where the virus circulates naturally or because changes in ecologic or environmental circumstances have caused the virus to move closer to areas inhabited by humans. Sometimes a different mosquito carries the virus to humans (a bridging vector), and sometimes there is an intermediate vertebrate cycle that brings the virus closer to humans (e.g., equines for some of the alphavirus encephalitides and swine for JEV). A large outbreak of disease in animals is an epizootic. Whereas natural hosts have prolonged and high viremia, humans have transient and low viremia, insufficient to transmit the virus further, and are considered “dead-end” hosts. Most human infections are asymptomatic or result in a mild nonspecific febrile illness, but in a small proportion, the virus enters the CNS to cause the syndrome for which the virus is known. The brief and low viremia makes diagnosis of human infection by virus isolation or nucleic acid amplification difficult, and for the most part, serologic tests are used. Although humans are “dead-end” hosts for most arboviruses, some arboviruses are better adapted to replicate in humans, resulting in persistent and high viremias, allowing for further transmission to a biting insect. Examples include VEEV, TOSV, CTFV, and DENV. These high viremias typically cause a characteristic arboviral “fever-arthralgia-rash” syndrome in most patients; CNS manifestations tend to be milder, for example, aseptic meningitis. Because of the high viremias, virus isolation and polymerase chain reaction (PCR) are more successful for these viruses.
Arboviruses replicate in both the vertebrate host and the vector in an “extrinsic” cycle. Whereas vertebrate hosts typically mount an immune response and clear the virus, the arthropod vectors are usually infected for life. Virus is ingested by the vector with an infected blood meal, replicates in the epithelium of the mesenteron (midgut), then disseminates to the salivary glands, where it replicates further and is excreted with each blood meal. The virus may also be passed on from the adult mosquitoes and ticks to their offspring, via transovarial transmission (Fig. 15.2). For ticks, virus can also be transmitted vertically from the larval to nymph then adult stages (transtadial transmission). Vertical transmission is an important means of overwintering (i.e., surviving the cool winter months) for some viruses, but for others, the means of overwintering is uncertain. An exception to a “typical” arboviral cycle includes mechanical transmission via the vector’s mouth parts. More importantly, some viruses, as well as being arthropod borne, can also be directly transmitted between vertebrate hosts, bypassing the arthropod vector, for example, humans can become infected with Rift Valley fever virus (RVFV) from the body fluids of infected animals (2), TBE virus can be transmitted to humans via infected goat’s milk (3), and WNV can be transmitted in infected blood products or transplanted organs (4).
PATHOGENESIS OF ARBOVIRAL ENCEPHALITIS
Despite the wide range of arboviruses that cause encephalitis, there are many similarities in the pathogenesis and pathology (see Table 15.2 for an overview of the arboviral encephalitides). Much of the data has come from rodent models of alphavirus encephalitis. Following inoculation, usually during the bite of a blood-sucking mosquito or tick, arboviruses typically replicate in the skin and local lymph nodes, causing a viremia, before entering the CNS (5). Langerhans cells in the skin have been implicated as a site of replication for alphaviruses and some flaviviruses (6–8). Keratinocytes have also been shown to be one of the initial targets for WNV replication and could be contributing to the persistence of WNV in the skin (9). Replication in local skeletal muscle may also be important for alphaviruses. Invasion of target organs appears to depend in part on the extent of viremia, but also on other invasive viral characteristics (10). The two peaks of the characteristic saddleback or biphasic fever curve seen in many arboviral infections correspond to production of interferon (IFN) and proinflammatory cytokines during the initial viremia, and then a mononuclear inflammatory response in infected target organs (11). IFN production is induced when viral components are detected by cytoplasmic proteins such as retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5) during the unwrapping of the viral RNA from the nucleocapsid to allow replication. In addition, cells use toll-like receptors (TLRs) to recognize pathogen-associated molecular patterns. TLR3, TLR7, TLR8, and TLR9 are the main viral sensors in humans. TLR7, TLR8, and TLR9 are localized in the endosomal compartments and signal through the MyD88 adapter, leading to type 1 IFNs and inflammatory cytokine production. TLR3 is located both on the cell surface and in endosomal compartments and induces production of type 1 IFNs through toll/interleukin-1 (IL-1) receptor (TIR) domain-containing adapter-inducing IFN-β (TRIF) adapter. Protein kinase R (PKR) and 2′, 5′-oligoadenylate synthetase (OAS) are two other cellular viral sensors. Viral sensors activate IFN regulatory factors and transcriptional induction of IFNs, which then signal through the JAK/STAT pathway leading to transcription of many interferon-stimulated genes (ISGs). The expression of ISGs and induction of their products (e.g., RIG-I, MDA5, TLRs, OAS, PKR) are critical for limiting replication of arboviruses. Many arboviruses encode nonstructural proteins to counter the host immune response. The main function of these nonstructural proteins is to antagonize the initial IFN response and is an important adaptation that has helped arboviruses to establish themselves in numerous vertebrate hosts (12).
The mechanisms of virus entering the CNS may include infection of or transport across brain microvascular endothelial cells that form the blood–brain barrier (BBB) and infection of olfactory neurons or of choroid plexus epithelial cells (13–16). However, the exact mechanisms of virus entry into the CNS across the BBB and interactions of the virus with the BBB remain incompletely understood, despite the critical role of the BBB in preventing pathogen entry to the CNS (17–20). In animal models, the term neuroinvasiveness is used to describe a virus’ ability to enter the nervous system following peripheral inoculation. “Neurovirulence” describes its ability to cause damage once within the CNS (e.g., following invasion from the periphery or following direct intracranial inoculation). Once inside the nervous system, the pathogenesis may involve a combination of infection and dysfunction of neurons, caused by direct viral or indirect inflammatory damage and other mechanisms such as programmed cell death. The immune response to alphavirus infection has been characterized in experimental animals and includes an early innate response with type I interferon (IFN-α and IFN-β) production, followed by specific humoral and cellular immune responses (21). Experiments with knockout mice have shown type I IFN limits early viral replication, possibly by production of MxA protein, a large cytoplasmic guanosine triphosphatase that prevents accumulation of viral genomic and subgenomic RNA (22). Tumor necrosis factor-α (TNF-α) and other proinflammatory cytokines are produced, contributing to the pathogenesis (23). Production of IFN-α and other cytokines and chemokines has been implicated in JEV in humans (24–26).
The humoral immune response in human alphavirus and flavivirus encephalitis includes early production of immunoglobulin M (IgM), followed by immunoglobulin G (IgG) that persists for years (27–30). The failure of antibody production is associated with a fatal outcome in human disease (30–32). Antibody appears to be protective by neutralization, nonneutralizing binding, and complement-mediated lysis of infected cells (33). In animal models of alphavirus encephalitis, antibody assists with nonlytic clearance of virally infected cells by a mechanism that appears to be synergistic with the effects of IFN-α (34). This may be especially important for clearing virus from the CNS, where limited expression of major histocompatibility class (MHC) antigens in mice (or human leukocyte antigen [HLA] antigens in humans) may restrict the role of T lymphocytes. Infiltration into the CNS of antibody-producing B cells has been demonstrated in animal models (35). Cellular immune responses to alphavirus infection include lymphoproliferative, cytokine, and cytotoxic. In alphavirus encephalitis, there is infiltration of natural killer cells, B cells, CD4, CD8 T cells, and macrophages. CD8 T cells may be important in virus clearance from infected macrophages (36). Studies on humoral responses to flavivirus infection have shown protection of mice by passive transfer of antibodies against lethal challenge by several flaviviruses (37–39). Furthermore, B cell–deficient mice were shown to be highly susceptible to flavivirus infection (37,40–42). In contrast, the role of T cells during flavivirus infection is less well characterized. A few studies have shown a protective role for CD4+ T cells by enhancing antibody production and sustaining flavivirus-specific CD8+ T-cell responses (43,44). CD8+ T cells have been shown to be important for clearance of virus and survival of mouse models of WNV (45–48), whereas cytotoxic T cells caused accelerated and more severe pathogenesis in mice infected with MVEV (49). In mice infected with JEV, CD8+ T cells did not affect the outcome of the infection. Therefore, a conflicting role for CD8+ T cells in flavivirus encephalitis is suggested (40).
PATHOLOGY OF ARBOVIRAL ENCEPHALITIS
Few data are available for CNS infections caused by coltiviruses and phleboviruses because they are rarely fatal. Pathologic studies of fatal human encephalitis caused by alphavirus, flavivirus, and bunyaviruses show many common findings (50–56). The leptomeninges are normal or slightly hazy, and histologic examination shows an inflammatory infiltrate. The brain parenchyma is congested with focal petechiae or hemorrhage. Lesions are distributed through the gray matter of the cerebral cortex, midbrain, basal ganglia, cerebellum, brainstem, and spinal cord, providing the anatomic correlates for many of the clinical features seen (see later discussion). Microscopically, there is perivascular cuffing, with infiltration of mononuclear and polymorphonuclear cells into the parenchyma, as well as neuronophagia of infected cells by glial cells. Immunohistochemical analysis of the lymphocyte populations typically shows CD4+ and CD8+ cells, which are presumed to be cytotoxic T cells. Similar changes are seen in animal models. Initially, there is perivascular infiltration of mononuclear cells, with a few polymorphonuclear cells, which is accompanied by perivascular extravasation of red blood cells (RBCs), endothelial cell swelling, and hyperplasia (57,58). This is followed by migration of lymphocytes and monocytes toward virus-infected neurons. The inflammation is accompanied by gliosis and by inflammatory and glial cell apoptosis (59). Demyelination is seen in encephalitis caused by some alphaviruses but does not seem to be important in the flaviviruses (60). Although the cellular immunity and the inflammatory response are important in most infections, some patients die from virally induced neuronal cell death before there is evidence of a cellular immune response and inflammation.
Various processes contribute to neuronal cell death including apoptosis, cytoplasmic swelling, vacuolation, and membrane breakdown (61). In some instances, alphaviruses are inadequately cleared from the CNS, as illustrated by detection of viral RNA in the brains of mice long after recovery (62,63). Chronic progressive human disease with continuing brain inflammation long after the acute disease has been reported in some alphavirus encephalitides (64). For example, persistent symptoms such as joint and muscle pains can last for several years post CHIKV infection (1). Chronic infection does not appear to be important for most of the mosquito-borne flaviviruses, but there is evidence of persistent infection and chronic inflammation for humans infected with TBEV and in animal models (65,66).
CLINICAL FEATURES OF ARBOVIRAL ENCEPHALITIS
The clinical syndrome following neurologic infection with an arbovirus depends on the site of attack. If the meninges are involved, meningitis results; inflammation of the brain parenchyma causes encephalitis; and damage in the spinal cord causes myelitis. The term meningoencephalomyelitis encompasses the concept that all three components may be affected. Despite the wide range of etiologic agents, there are many similarities in the clinical presentations of arboviral encephalitis. After a brief incubation period, which typically is 4 to 8 days but may range from 1 to 28 days, patients develop a nonspecific flulike illness with fever, headache, nausea, and vomiting. Often, there are upper respiratory tract symptoms, such as cough and sore throat, or abdominal pain and diarrhea. Sometimes, a rash, conjunctival or pharyngeal injection, or lymphadenopathy may give a clue to the diagnosis. This may be seen for the “fever-arthralgia-rash” viruses, for example, WNV, DENV, CTF, TOSV, or VEEV. The febrile phase usually lasts a few days and may immediately be followed by continued fever with the development of neurologic symptoms and signs, or there may be an intervening asymptomatic period, thus giving a “saddleback” or biphasic fever curve characteristic of some arboviral infections, such as TBE or CTF. Neurologic disease may manifest as subtle changes in behavior, or mutism, resulting in an initial misdiagnosis of psychiatric illness. More often though, there is a profound reduction in consciousness level, which in children may be heralded by seizures. Seizures and status epilepticus are especially common in children with JEV and LACV encephalitis (67,68). As well as obvious generalized tonic-clonic seizures, subtle motor status epilepticus is being increasingly recognized. A great range of focal neurologic signs may be seen in arboviral encephalitis, including those of upper motor neuron damage, such as a hemiparesis, and cranial nerve signs indicative of brainstem damage. Flaccid limb weakness due to destruction of the anterior horn cells in the spinal cord is seen in flavivirus encephalitis and EEEV. Most flaviviruses can also cause a poliomyelitis-like flaccid paralysis that typically affects the lower limbs for mosquito-borne flaviviruses such as JEV, WNV, and Murray Valley encephalitis (MVE), and the upper limbs for TBE (69–71). Extrapyramidal signs are common in both alphavirus and flavivirus encephalitis and are thought to be the clinical correlates of the basal ganglia damage evident pathologically and radiologically, including increased tone causing generalized axial and limb rigidity, or rigidity/spasm such as opisthotonus, and tremors of the limbs, eyelids, and tongue.
DIFFERENTIAL DIAGNOSIS OF ARBOVIRAL ENCEPHALITIS
The differential diagnosis of arboviral encephalitis is broad and includes other causes of viral encephalitis (Table 15.3), as well as diseases that mimic viral encephalitis (Table 15.4). Certain epidemiologic features may give a clue that a patient has an arboviral infection. For example, in parts of Asia, epidemics of JEV occur with great predictability after the start of the rainy season. In the Americas, the alphavirus equine encephalitides are typically associated with illness in horses. More recently, birds falling from the sky have heralded the arrival of WNV. The age and occupation of the patient can also point to epidemiologic risk factors. JEV tends to affect children in rural parts of Asia, recent WNV encephalitis outbreaks have affected the elderly or patients on immunosuppressive drugs, and LACV encephalitis tends to affect children. A recent tick bite may suggest TBE in Europe, Russia, and the Far East, or CTF in parts of North America, though other tick-borne diseases, such as borreliosis, ehrlichiosis, and rickettsial disease must be considered. A biphasic illness is characteristic of some arboviral encephalitides. On examination, certain neurologic signs may suggest a patient has arboviral encephalitis rather than encephalitis caused by herpes or other viruses. For example, in an unconscious patient, the presence of flaccid limbs consistent with anterior horn cell damage, or the tremors, increased tone, and rigidity spasms suggestive of basal ganglia damage may suggest an arboviral cause.
INVESTIGATION AND DIAGNOSIS OF ARBOVIRAL ENCEPHALITIS
A mild leukocytosis is common in many arboviral encephalitides, but leukopenia with thrombocytopenia is sometimes seen in TBE and CTF. Hyponatremia due to a syndrome of inappropriate antidiuretic hormone (SIADH) secretion is common, and in some infections, alanine transaminase may be mildly elevated. In Western settings, lumbar puncture is often delayed in severely ill patients until imaging has ruled out a space-occupying lesion, or incipient brainstem herniation. In many tropical settings where imaging is not available, lumbar punctures are performed on most encephalopathic patients who do not have signs of brainstem damage because of the importance of excluding other treatable causes, particularly bacterial infections (72,73). Lumbar puncture will often reveal mildly elevated cerebrospinal fluid (CSF) opening pressures (up to 250 mm of CSF), a lymphocytic pleocytosis with a normal CSF-to-plasma glucose ratio, and slightly elevated protein level. However, an early lumbar puncture may reveal no cells, or a neutrophil predominance, rather than a lymphocytic CSF. A low glucose ratio has been reported for EEEV and CTF, whereas an elevated ratio has been reported for VEEVs. Radiologic investigations may be helpful in excluding other conditions and in highlighting changes such as the high signal intensity seen on magnetic resonance imaging (MRI) in the thalamus and basal ganglia that characterizes both alphavirus and flavivirus encephalitis (74). Computed tomography (CT) scans may show low signal in the same areas or just edema. Although they do not reveal diagnostic information, electroencephalograms (EEGs) can help identify seizures (particularly the subtle motor seizures described earlier) and distinguish focal seizures from tremors.
For most arboviral infections of humans, viremias are so low and brief that they are undetectable by the time a patient comes to the hospital (75) (Fig. 15.3); exceptions are the viruses for which humans are important natural or amplifying hosts, such as DENV, VEEV, and TOSV. Virus may also sometimes be isolated from the CSF, particularly for infections that prove fatal, or from brain tissue at either biopsy or autopsy. The traditional method for virus isolation was inoculation into suckling mice, but this has largely been replaced by continuous cell lines (e.g., C6/36 cells derived from Aedes albopictus mosquitoes, and Vero cells derived from African green monkey kidney). Amplification by PCR of viral nucleic acid in the CSF or serum tends to be more sensitive than virus isolation, particularly if real-time Taq-Man PCR is used and has helped with diagnosis of WNV and TOSV infections, although false-positive results do occur. Immunohistochemistry of brain tissue may demonstrate viral antigen in fatal cases, and antigen-capture enzyme-linked immunosorbent assays (ELISAs) have been developed, but they have limited utility.
Serologic methods to detect antiviral antibody are the mainstay of the diagnosis of arboviral infections. The traditional techniques such as hemagglutination inhibition, complement fixation, indirect immunofluorescence, and neutralization tests require the demonstration of a greater than fourfold rise in antibody titer in samples taken several weeks apart and thus have practical limitations; for example, they do not give a diagnosis acutely and are not helpful in patients who die or are lost to follow-up. However, they do have specific research uses. For example, hemagglutinating antibodies are often broadly cross reactive, so in a patient with an undiagnosed encephalitis, a panel of antigens can be used to indicate whether a patient was infected with a flavivirus, an alphavirus, a bunyavirus, or other virus; this can then be followed by more specific tests within that group. Neutralizing antibodies persist for life, so they can be used for serologic surveys to indicate whether individuals have ever been infected with a virus. In recent years, IgM and IgG capture ELISAs have become the most useful and widely deployed tests for diagnosing arboviral encephalitis. Depending on the virus, typically 50% of patients have antibody on admission to hospital, and more than 90% have antibody 1 week later, so in patients whose initial test results are negative, the test should be repeated after 1 week (Fig. 15.3). Although they are the most useful tests, ELISAs too have their limitations. For example, because closely related viruses have many shared epitopes, there may be cross reactivity in IgM and IgG capture ELISAs between the viruses. This problem can usually be overcome by testing for the related viruses in parallel, with the strongest reaction indicating the infecting agent. However, sometimes a neutralization test, which is more specific, may be needed. Importantly, antibody will be detected in the serum of individuals who have had recent asymptomatic or febrile infection but no neurologic disease. Its detection in the CSF is usually taken as a better indicator of viral replication in the CNS. Finally, some patients may make antibody late or not at all. These patients are more likely to die and to have virus detected by another means such as isolation or PCR.
Newer approaches for detection of flaviviruses antibody include the lateral flow assay and the microsphere immunoassay (MIA). The lateral flow device was recently approved by the U.S Food and Drug Administration (FDA) for the diagnosis of WNV infection in humans, which can give a result in 15 minutes (76). In MIA, an antigen is attached to encoded microbeads that will bind the target analytes during the assay procedure. These can then be identified using a fluorescence-activated cell sorting system (FACS). MIA is used by many laboratories in the United States for WNV diagnosis as it is highly sensitive compared to a standard ELISA. Furthermore, one serum sample can be analyzed for reactivity to several antigens in a single assay (77). Other approaches include high-throughput rapid microneutralization assays, biosensor-based assays, microfluidic systems based on virus-coated magnetic beads, and multiplex real-time RT-PCR assays (78–81).
TREATMENT OF ARBOVIRAL ENCEPHALITIS
There are no established antiviral drugs for any arboviral encephalitides. IFN-α, ribavirin, and intravenous immunoglobulins have been given to patients with flavivirus encephalitis, based on in vitro and animal data. However, the few clinical data available suggest that IFN-α is not effective in JEV (82). In the West, most patients with encephalitis will be given acyclovir until herpes simplex virus type 1 (HSV-1) encephalitis has been ruled out. The management of arboviral encephalitis focuses on treating the complications of disease, in particular hyponatremia, seizures, and increased intracranial pressure (ICP). In most Western settings, severely ill patients will be electively ventilated and managed in intensive care settings, allowing airway protection, seizure control, optimal assessment of fluid balance, and hyperventilation to reduce increased ICP. However, in many of the settings in which arboviral encephalitis occurs, this is not possible. At a minimum, patients at risk of raised ICP should be nursed at 30°C, with the neck held straight to ensure the jugular venous outflow is not impaired and with urine output monitored and oxygen given.
Seizures are common, particularly in children with flavivirus and bunyavirus infections. In addition to obvious tonic-clonic seizures, subtle motor seizures may be indicative of subtle motor status epilepticus (68). An EEG is advisable, particularly in patients with twitching of a finger, lip, or eyelid. Simple or complicated seizures should be managed according to local standard of care (83–85) (see Chapter 1 where the management of the critically ill patient with CNS infections is discussed). A few specific notes relating to arboviral encephalitis are indicated. Attention to the etiology of increased ICP is of the greatest importance (86,87). In many encephalopathies, if the blood pressure is well maintained, but increased ICP is suspected, 20% mannitol (0.5 to 1.0 g/kg) is given, although the little evidence available suggests the benefits, if any, are only short term (68,88). Steroids are sometimes given, although they were not shown to be beneficial in JEV (89). Hypoglycemia is common in many tropical pediatric conditions (90) and must be looked for and corrected.
PREVENTION OF ARBOVIRAL ENCEPHALITIS
A consideration of the typical arboviral ecologic cycle (Fig. 15.1) reveals points at which intervention might be effective. These can be divided into measures to interrupt the natural cycle, measures to stop humans being bitten by infected vectors, and measures to stop infection resulting in disease (i.e., vaccination). For most of the arboviruses that cause encephalitis, because the natural cycle involves small wild birds and rodents, interrupting this cycle is not possible. However, when an intermediate or amplifying vertebrate host brings the virus closer to humans, for example, equines for VEEV and swine for JEV, measures can be taken. For example, vaccines that protect horses against VEE probably also reduce the number of human cases. Immunization of swine against JEV has been practiced in Asia, though with limited success. However, relocation of swine away from homes is probably a more effective way of reducing transmission of JEV to humans. Surveillance of mosquitoes, dead birds, and sentinel chickens (i.e., chickens deliberately exposed to mosquito bites) for viral infection is used in many Western settings as an indicator of viral activity and possible impending human disease, and antimosquito measures are then implemented. Interventions to reduce the number of circulating mosquitoes depend on the species and the setting. Measures include removing stagnant water from swampy areas, ditches, and drains favored by many Culex species and removing the freshwater containers (car tires, tree holes, litter) favored by Aedes species. Larvicides can also be applied to potential breeding sites (either biologic larvicides such as Bacillus thuringiensis variance israelensis or the chemical larvicide, metoprine). With continuing human cases, public health authorities have practiced ground or aerosol spraying with pyrethroid formulations that kill adult mosquitoes. Newer interventions are under development including the sterile insect technique and the Wolbachia-based strategies to control Aedes species (91–94).
For many of these measures, evidence of beneficial impact is limited, but they demonstrate that public health authorities are taking the situation seriously. Personal measures to reduce the chance of being bitten by infected vectors are important. These include using repellents that contain 10% to 30% DEET (N, N-diethyl-3-methyl benzamide) on skin and clothing, applying permethrin insecticides on clothes, and wearing long-sleeved shirts and trouser. In areas where tick-borne viruses circulate, regular inspection of the limbs ensures no ticks are attached. Many of the Culex vectors bite at night, and the use of impregnated bed nets is recommended. Public education is an important part of any of these measures. For some flaviviruses (e.g., JEV and TBEV), inactivated or live attenuated vaccines are available, although their use is limited by cost and availability. The dramatic reduction in TBE in Austria following widespread vaccination demonstrates feasibility. However, because most of these viruses are enzootic, eradication by vaccinating humans is not possible. For other arboviral diseases, the sporadic nature and low incidence mean that the vaccines would not be economically viable, even if they existed.
ALPHAVIRUSES
The alphavirus genus is one of two important genera in the family Togaviridae (named after the cloak, or toga that envelops the viruses) (11). Whereas alphaviruses are arthropod-borne members of the other genus, the Rubivirusgenus organisms (e.g., rubella virus) are not arthropod borne and so are not considered further here (Table 15.1). Alphaviruses cause two clinical syndromes. In Africa, Old World alphaviruses CHIKV and o’nyong-nyong virus cause large outbreaks of fever arthralgia and rash; a similar syndrome in which arthritis is predominant is caused by Ross River virus in Australia. In the Americas, New World alphaviruses EEE, WEE, and VEE viruses cause outbreaks of encephalitis in horses and humans and are the focus of this section (Table 15.2). EEE is notable for having a higher case-fatality rate than other viruses in the group, whereas WEE is remarkable because although it has caused large outbreaks in the past, it has now virtually disappeared as a disease of humans. Although VEEV causes encephalitis in equines, in humans it causes a febrile disease, with only a small proportion developing usually mild CNS disease. Two other alphaviruses, Sindbis virus and Semliki Forest virus, have animal models of the pathogenesis of alphavirus encephalitis. Phylogenetic analyses suggest that the alphaviruses arose in the New World with subsequent introductions into the Old World. The WEE lineage appears to have derived as a recombinant of an ancestral EEE-like and Sindbis-like viruses (95).
Infectious Agent
Alphaviruses consist of a single strand of positive-sense RNA wrapped in a nucleocapsid and surrounded by a glycoprotein-containing lipid membrane that is derived from host cell plasma membrane (11). The virion is 60 to 70 nm in diameter. The 11to 12-kb RNA has a 5′ cap and a 3′ polyadenylated tail. It consists of message-sense RNA that is directly infectious. It codes from the 5′ to the 3′ end for four nonstructural proteins, nsP1, nsP2, nsP3, and nsP4, and five structural proteins—capsid (C), envelope 3 (E3), E2, 6K (a 6-kd protein), and E1. The nonstructural proteins are involved in replication of the viral RNA and production of subgenomic RNA. The C protein has a conserved end with many basic amino acids and is presumed to bind the viral genomic RNA to form the nucleocapsid. This nucleocapsid is an icosahedron with T = 4 symmetry. The E1 and E2 glycoproteins project from the lipid membrane, forming heterodimers that group as trimers to form 80 knobs on the virion surface (96). Alphaviruses gain entry into cells by attaching to the cell surface and entering via the endocytic pathway to form vesicles. As the pH level of the vesicles decreases, the E1/R2 heterodimer dissociates, revealing a highly conserved hydrophobic sequence in E1. This is thought to act as a fusion peptide, causing viral membrane and host cell membrane to fuse, and thus releasing the viral nucleocapsid into the host cytoplasm. Here the nucleocapsid is uncoated of its capsid protein so that naked RNA is exposed to ribosomes for initiation of translation as the first step of viral replication. Virus is replicated in association with the endoplasmic reticulum and Golgi apparatus, and new virions are released by budding at the host cell surface.
Eastern Equine Encephalitis
Epidemiology
EEE virus was first isolated from the brain of a horse that died during an epizootic of equine encephalitis in New Jersey and Virginia in 1933 (97). The first human isolate was made 5 years later. The geographical area affected by EEE extends from Ontario and Quebec provinces in Canada, down the eastern seaboard of the United States, and into South America as far as Argentina. To the West, the area extends as far as Wisconsin and eastern Texas. The virus is transmitted between wading birds, passerines, and other swamp birds by Culiseta melanura and other mosquitoes. It has also been isolated from crows (98). These mosquitoes are strictly ornithophilic (bird biting). However, other mosquitoes that feed on both birds and mammals serve as bridging vectors carrying the virus to horses, humans, and other mammals (Fig. 15.2, Table 15.2). In South America, rodents and marsupials may be more important natural hosts than birds. Outbreaks of disease have also occurred in commercial flocks of pheasants, partridges, turkeys, and emus (99). In these circumstances, direct transmission between birds because of preening and pecking and transmission via the fecal-oral route have also occurred. The means by which the virus persists during the winter is not known, but persisting viremia in birds or vertical transmission into mosquito eggs has been postulated. Cases occur year round but are more likely in the summer, especially when associated with increased rainfall, which by creating a high water table augments the breeding habitat of C. melanura.
EEE usually occurs as single cases and rarely as clusters that may be preceded by disease in horses. The median annual number of cases in the United States is three (range, 1 to 14), and the reported incidence is less than 0.1 to 0.4 per 107. Seroepidemiologic studies show that humans are only rarely infected with the virus. Fewer than 7% of residents older than 45 years had antibody in one study (100). Most infected patients are asymptomatic with a ratio of symptomatic to asymptomatic infections of about 1 in 30. However, the elderly and young children are more likely to develop disease.
Clinical Features
After an incubation period, which is thought to range from 3 to 10 days, patients present with a few days of febrile prodrome and then neurologic disease. Early symptoms include headache, myalgia, photophobia, abnormal sensations, vomiting, dizziness, and lethargy, followed by neck stiffness, a reduced level of consciousness, and seizures. In infants, progression to coma may be more rapid, occurring over 48 hours. On examination, a high pyrexia (>39°C) is common and one third of patients have signs of meningismus. Clinical signs suggestive of brainstem involvement include gaze deviation, nystagmus, and papillary abnormalities. This may be because of inflammatory lesions in the brainstem, but uncal and subtentorial herniation have been seen at autopsy. Hemiparesis and limb spasticity suggest upper motor neuron involvement, whereas flaccid limbs suggest involvement of lower motor neurons in the spinal cord. Seizures may be generalized or focal. In patients who remain conscious, aphasia and emotional lability may occur. Limb dysesthesia and flaccid paralysis have also been reported in a fully conscious patient, suggesting myelitis may occur without brain involvement (101). Approximately one third of patients die, but for those older than 60 years, the proportion is 50%. One third of survivors have moderate or severe sequelae (102).
Diagnosis
Peripheral leukocytosis, with neutrophil predominance can occur. The CSF resembles that of acute bacterial meningitis with a neutrophil pleocytosis (as high as 5,000 cells/mm3); the RBC count and protein level are often elevated, and the glucose ratio is less than 50% in half of the patients (102,103). CT scans show diffuse cerebral edema in most patients. On MRI, lesions that do not enhance with gadolinium are seen in the basal ganglia, thalamus, and brainstem (102). EEGs show background and focal slowing, as well as burst suppression. High-voltage delta waves carry a poor prognosis (103).
Virus isolation from the blood is unusual, although it has been reported for EEE early in the illness (101). In fatal cases, virus may be isolated from brain tissue or detected by PCR or immunohistochemical staining. In most cases, the diagnosis is made serologically by detecting antibody in the blood. Older serologic tests such as hemagglutination inhibition, complement fixation, and neutralization tests are being replaced by IgM capture ELISAs, which detect antibody in a single blood or CSF sample, thus providing an earlier diagnosis.
Treatment and Prevention
Because there are no antiviral drugs, treatment is focused on the complications of infection, particularly seizures and raised ICP and pneumonia. No vaccine against EEE is commercially available, although an inactivated vaccine is used by laboratory workers and others at high risk (104). Recently, a chimeric Sindbis (SINV)/EEEV candidates have been shown to be safe and effective against protecting mice against EEEV (105). A similar vaccine is used to protect horses. Personal protective measures against mosquito bites are described earlier in this chapter.
Western Equine Encephalitis
Epidemiology
The isolation of WEE virus from the brain of horses during an epizootic episode of unknown etiology in 1930 in the San Joaquin Valley of California marked the first time an arbovirus was isolated in the territorial United States (106). Subsequently, in 1938, WEE virus was obtained from a child who succumbed to encephalitis (107). Virus activity has been reported from western Canada, the western and midwestern United States, and as far south as Argentina. In the western United States, WEE virus is transmitted between passerine birds (sparrows and house finches) by Culex tarsalis mosquitoes. Epidemic and epizootic activity occurs mainly in the summer months. Highlands J virus, which is found in Florida, is one of several related viruses in the WEE complex that do not appear to cause disease in humans (108).
Clinical Epidemiology
Until recently, exposure to WEE virus was common, with up to 20% of humans having antibodies in some areas. However, a decline in the rural population and changes in land use have meant that even in areas where the virus circulates, this figure is now less than 1% (109). The largest outbreak was in 1941, with more than 3,000 human cases and hundreds of thousands of equine cases (110) and an estimated incidence of 167 per 100,000 in North Dakota, but since the 1990s, there have been only a handful of reported cases each year. The ratio of apparent to inapparent infections is estimated to be fewer than 1 in 1,000 in adults and 1 in 60 in children.
Clinical Features
The clinical features of WEE tend to be milder than those of EEE. After an incubation period, which ranges from 2 to 10 days, there is a nonspecific febrile prodrome before neurologic disease. Meningismus is seen in half the patients, and although weakness and tremors are common, fewer than 10% of patients develop coma (111). Focal signs include cranial nerve palsies, hemipareses, hyporeflexia, spasticity, generalized rigidity, and occasionally opisthotonus. The overall case-fatality rate is approximately 4% to 10% (112), being higher among the elderly. WEE virus is more severe in infants, with rapid progression from nonspecific illness to convulsions and coma. Transplacental infection has been reported (113). The overall case-fatality rate is 3%, increasing to 8% for those older than 50 years (114). Neurologic sequelae are common in young children. Parkinsonian features including cogwheel rigidity and tremors have also been reported (115).
Diagnosis
The peripheral white blood cell count is usually normal or mildly elevated. Hyponatremia due to SIADH has been reported. CSF opening pressures of more than 200 mm occur in two thirds of patients. CSF white blood cell counts are usually less than 100 cells/mm3 but may range from less than 10 to 500 cells/mm3 with lymphocyte predominance, a slightly elevated protein level, and a normal glucose ratio. CT scans have been reported as normal, but EEGs show diffuse slowing with focal delta activity in the temporal region, which may mimic HSV-1 encephalitis (116). WEE virus is occasionally isolated from the CSF or from diagnostic brain biopsies (117). Detection of IgM in the CSF or serum is the preferred diagnostic test (30).
Treatment and Prevention
There is no specific treatment, although equine immune serum was used following laboratory exposure in one patient (118). A nonlicensed inactivated vaccine is available for laboratory workers and others at high risk (119). A recent study has shown the potential of an adenovirus-vectored WEEV vaccine, Ad5-WEEV, for development into an emergency vaccine during an outbreak of WEEV (120). Furthermore, a human adenoviral vector (Ad5-mIFNα) expressing mouse IFN-α was shown to offer 100% protection against mice challenged with various WEEV strains (121). Surveillance and vector control measures are practiced in some areas where the virus circulates.
Venezuelan Equine Encephalitis
Epidemiology
VEEV was first isolated from the brains of dead horses in 1938 (122), and subsequently six antigenically related subtypes (I through VI) have been identified based on serologic cross reactivity (123). Tonate virus is a subtype IIIB VEE complex virus that circulates in French Guiuan and has caused encephalitis (124,125). Subtype I viruses were further subdivided serologically into IAB, IC, ID, IE, and IF. More recent molecular genetic studies suggest a revision of some of these groups. VEEV circulates in an enzootic sylvatic (forest) cycle (Fig. 15.2) and emerges to cause major epizootics in horses and human epidemics every 10 to 20 years. Sylvatic VEEV is found in Central and South America, and although most epizootics have occurred in northern South America, particularly Venezuela and surrounding countries, they have extended as far north as Mexico and Texas (21,85,126). In its sylvatic cycle, VEEV is transmitted between small mammals and aquatic birds mainly by Culex melanoconion mosquitoes (Table 15.2). Sporadic human cases occur when people enter the swampy and forested locations where the viruses circulate or when bridging mosquitoes such as Aedes taeniorhynchus carry the virus to nearby human habitats. In contrast, human epidemics occur at the same time as equine epizootics when the virus emerges from its enzootic cycle and is transmitted between susceptible horses by Aedes, Psorophora, Mansonia, and Deinocerites mosquito species. Some studies suggest that the E2 protein encodes mosquito infection determinants for VEE, suggesting selection for efficient infection of epizootic mosquito vectors may mediate VEE emergence (127). Major epizootics and epidemics of VEE have occurred every 10 to 20 years in cattle-ranching areas of Venezuela, Peru, Colombia, and Ecuador. Although epizootic viruses (subtypes IAB and IC) were originally thought to be maintained in a separate transmission cycle from enzootic viruses (subtypes 1D, 1E, or 1F), later studies have suggested that epizootic IC viruses arise by mutation from sylvatic ID viruses (128–131). The 1C strains remain in the sylvatic cycle until the ecologic factors support its emergence into the epizootic cycle. Such outbreaks occur when heavy rainfall and flooding expand the mosquito breeding habitats and support expansion of the rodent population but also require a large susceptible equine population. Outbreaks of VEE IAB subtype that spread to Central America and Texas in the late 1960s and early 1970s are thought to have originated from improperly activated equine vaccine strains, as indicated by the fact that the epizootic strains are genetically almost identical to the vaccine strains (132).
Seroprevalence studies indicate that up to 50% of the population have antibody to VEEV in some sylvatic areas, whereas the remainder of the population is immunologically naive until an outbreak occurs. During the 1995 outbreak of VEE in Venezuela and Colombia, an estimated 85,000 human cases occurred, of which 3,000 had neurologic disease and 300 were fatal (128,133). One third of the human population seroconverted, and 8% of the equines died. Unlike most of the other arboviral encephalitides, human viremias are sufficiently high to infect mosquitoes, suggesting humans may not always be dead-end hosts. Isolation of virus from the pharynx of up to 40% of patients suggests direct spread between humans is possible (134). No epidemiologic evidence of such spread has ever been demonstrated (133,134).
Clinical Features
Compared with the other alphavirus encephalitides, only a very small proportion of symptomatic VEE infections results in severe neurologic disease. The incubation period is brief (<1 to 5 days), and most patients then develop a febrile illness with severe headache, made worse by eye movements, photophobia, facial flushing, conjunctival injection, myalgia, arthralgia, nausea, vomiting, and dizziness. Pharyngeal inflammation and pain associated with cervical lymphadenopathy is common, and there may be subcostal tenderness (133,135,136). Somnolence and tremulousness occur often. More severe neurologic features occur in 4% to 14% of patients, particularly the young and elderly. Seizures, particularly focal seizures, and raised ICP are common (133,137). In 5% to 10% of hospitalized patients, cranial nerve palsies, motor weakness, paralysis, or cerebellar signs are reported. Respiratory tract infections, including interstitial pneumonia and tracheobronchitis, are common and may result in secondary bacterial infection. Overall, 0.2% to 1.0% of symptomatic VEE infections are fatal, but this increases to up to 10.0% to 25.0% of those with encephalitis. Children are estimated to have ten times the risk of neurologic disease of adults, and younger children have a greater case-fatality rate.
Diagnosis
Rather like the arboviral fever-arthralgia-rash syndromes, VEEV infection is typically associated with a leukopenia and elevated serum aspartate amino transferase levels (135). When lumbar punctures are performed, the CSF reveals a lymphocyte pleocytosis that may reach several hundred cells/mm3 and is reported to be associated with an elevated CSF glucose level. As expected, given the relatively high viremias, VEEV can be isolated from blood and pharynx up to the eighth day of illness and can be detected by PCR (134). VEEV antibody can be detected by IgM capture ELISAs (138). A VEEV-specific blocking ELISA that also identifies serotype-specific antibodies against VEEV in sera of humans, equids, or rodents has been reported (139).
Treatment and Prevention
There is no antiviral treatment for VEE. Supportive measures include attention to seizures and increased ICP. Equine vaccines for VEE interrupt transmission during outbreaks and prevent epizootics. An inactivated vaccine has largely been replaced by a live vaccine (TC-83), attenuated by serial passage in guinea pig heart cells (140). VEEV is considered a useful agent for biological warfare, because of its potential for droplet spread and tendency to cause an incapacitating flulike illness, rather than a fatal encephalitis, and for this reason, the vaccine was produced by the U.S. military. TC-83 is given to laboratory workers and produces neutralizing antibodies in more than 80% of recipients; however, it is associated with a high incidence of adverse events including fever and aseptic meningitis (37%). Most of those who do not respond immunologically to the vaccine seroconvert when subsequently given a killed vaccine (TC-84). An improved genetically engineered vaccine V3526 is being developed (141,142). Another vaccine candidate in development is the recombinant, chimeric Sindbis/VEEV (SIN-83) that is more highly attenuated than TC-83 (143,144). In addition, the use of antisense technology and humanized monoclonal antibody has been shown to be effective against mice infected with VEEV (145,146).
Chikungunya Virus
Epidemiology
A large outbreak of a disease locally known as “Chikungunya” in the Newala district of Tanganyika (now Tanzania) occurred in 1952 to 1953 (147). However, CHIKV may have caused outbreaks as early as 1779 as the disease was frequently mistaken with dengue (148). In the local language, Chikungunya means “the disease that bends up the bones.” CHIKV was first isolated in 1952 from the serum of a febrile human during this outbreak (147,149). Although initially assessed as a dengue outbreak, further characterization of the isolates by serologic and antigenic techniques indicated that CHIKV was an alphavirus (150). Since then, frequent outbreaks of CHIKV have been reported from many African and Asian countries. There are three CHIKV genotypes (West African, East/Central African, and Asian) but only one CHIKV serotype, and therefore, infection with a given genotype should result in lifelong immunity against any genotype (151).
In Africa, CHIKV typically circulates in a sylvatic, enzootic cycle involving wild primates and forest-dwelling mosquitoes with sporadic infection of rural human populations. The principle enzootic mosquito vectors include Aedes furcifer-taylori (southern and western Africa), Aedes africanus (central Africa), Aedes luteocephalus and Aedes dalzieli (Senegal), Aedes cordellieri (South Africa) and Aedes neoafricanus. Human migration has attributed to the introduction of CHIKV to the urban setting, where human-to-human transmission occurs through domestic and peridomestic mosquito vectors. The main domestic vector, Aedes aegypti has been responsible for the major outbreaks of CHIKV in Comoros, India, Kenya, Seychelles, and Singapore during the early phases of the global emergence of CHIKV during 2004 to 2011 (151,152). However, during the later phases (2006 onward), genetic adaptation of CHIKV to a new vector, A. albopictus led to major outbreaks in several Indian Ocean islands (Reunion Island, Sri Lanka), India, and Southeast Asian countries (Singapore, Malaysia and Thailand) (153,154). The Indian outbreak resulted in an estimated 1.4 million cases during 2006 to 2009, whereas an estimated 266,000 cases (258 deaths) in the Reunion Island were reported, with an overall attack rate of 34% during 2005 to 2006 (152,155). Later studies confirmed that the epidemics in the Indian Ocean islands and in India were associated with an amino acid substitution in the E1 envelop glycoprotein (E1-A226V) in CHIKV, which allowed the virus to adapt for dissemination by A. albopictus. A further mutation (E2-L210Q) has been described in the 2009 Indian outbreak, which again resulted in an increase in the dissemination of CHIKV in A. albopictus (156). Autochthonous transmission of CHIKV has been reported in Italy (2007) with over 250 cases and in France (2010), signaling the emergence of CHIKV in Europe for the first time (157,158). Imported cases of CHIKV infection have now been reported in several European countries, Australia, and the Americas (159–161).
Clinical Features
The clinical features of CHIKV infection have some similarities with dengue infection (162). Asymptomatic CHIKV infections are rare. After an incubation period that can range from 1 to 12 (average of 2 to 4) days, a sudden onset of high fever followed by severe arthralgia and a skin rash develops. Almost all CHIKV patients have symmetrical polyarthralgia. The most affected joints are the fingers, wrists, ankles, elbows, toes, and knees. The fever can reach as high as 40°C and may last up to 10 days. A transient maculopapular and erythematous rash on the face, limbs, and torso is common and may last for 2 to 3 days. Other symptoms include myalgia, headaches, photophobia, lumbar back pain, chills, weakness, malaise, nausea, and vomiting (151,163). The acute phase of CHIKV infection usually resolves within 1 to 2 weeks, but the arthralgia may persist for many months or years in some patients (164,165). Age and underlying joint disorders have been shown to increase the likelihood of developing persistent arthralgia. The case-fatality rate for CHIKV is about 0.1%, with most deaths occurring in the elderly, neonates, and adults with an underlying disorder. Heart failure, multiple organ failure, hepatitis, and encephalitis are the most common causes of death (163).
CHIKV has not been generally considered to be a neurotropic virus. However, reports from recent outbreaks have given strong evidence of neurologic involvement of CHIKV. The main neurologic manifestations of adults infected with CHIKV are encephalopathy, acute flaccid paralysis, and Guillain-Barré syndrome (166–169). A recent study has reported that about 25% of adults admitted with atypical CHIKV infection during the 2005 to 2006 Reunion Island had neurologic involvement (mainly encephalitis, malaise, and meningoencephalitis) (170). Neurologic manifestations were more common in children. The most common manifestations were encephalitis, febrile seizures, and acute encephalopathies (171). For the first time, vertical transmission of CHIKV, from mother-to-child was reported during the Reunion Island outbreak. Encephalopathy was the most common neurologic manifestation among newborns infected by vertical transmission (172).
Diagnosis
A possible CHIKV case is suspected when a patient is presented with an acute onset of high fever and severe arthralgia unexplained by other medical conditions. The case becomes probable if the patient is living or has visited an endemic area within 15 days before onset of symptoms. The case is confirmed when the patient test positive for one of the diagnostic laboratory tests for CHIKV (163). Diagnosis of CHIKV is made during the acute phase of infection by detection of viral RNA in serum samples by RT-PCR and by virus isolation. Viral RNA can be detected in samples obtained from 1 day before symptom onset to day 7. Real-time RT-PCR assays capable of detecting a region of the nonstructural protein (nsp1) gene or the envelope (E) gene are also used for diagnosis (173,174). For later samples, indirect immunofluorescence and ELISA can be used to rapidly and sensitively distinguish between IgG and IgM antibodies. CHIKV antigen can be detected in serum and CSF samples obtained 2 days after onset of symptoms by antigen capture ELISA. Several commercial serologic assays as well as in-house ELISA techniques have been used for CHIKV diagnosis and have been shown to accurately distinguish CHIKV from other alphaviruses (except o’nyong-nyong virus) and flaviviruses (175–177).
Treatment and Prevention
Nonsteroidal antiinflammatory drugs are the only recommended treatment for arthralgia caused by CHIKV infection. Ribavirin, chloroquine, and passive transfer of antibodies are other potential treatments being investigated (163,178). Vector control remains the main method of CHIKV prevention (91,179). Several vaccine candidates are under development. These include inactivated, whole-virus, DNA-based, viruslike particle, and adenovirus-vectored vaccine approaches as well as a chimeric alphavirus vaccine (105,180–183).
FLAVIVIRUSES
Infectious Agent
There are three important genera in the family Flaviviridae: the genus Hepacivirus, which includes hepatitis C virus, the genus Pestivirus, which includes bovine viral diarrhea viruses, and the genus Flavivirus(Table 15.1). This genus includes many important causes of arboviral encephalitis, as well as arboviral fever-arthralgia-rash and hemorrhagic fever syndromes, such as dengue viruses and yellow fever virus (Fig. 15.1). The genus and family are named after the Latin word for yellow (flavus). Flaviviruses are thought to have evolved from a common ancestor as recently as 10,000 years ago and are rapidly evolving to fill new ecologic niches (184,185). They consist of a single strand of positive-sense RNA, wrapped in a nucleocapsid and surrounded by a glycoprotein-containing envelope. The RNA comprises a short 58 untranslated region (UTR), a longer 38 UTR, and between them a single open reading frame (186). This codes for a single polyprotein, which is cotranslationally and posttranslationally cleaved by viral and host proteases into three structural proteins (core, or C, premembrane, or PrM, and envelope, or E), and seven nonstructural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The C protein is highly basic and combines with the RNA to form the nucleocapsid. The PrM is closely associated with the E protein, forming a heterodimer, and is thought to act as a “chaperone” to it, impairing its function until after virion release. Immediately before virion release, the PrM protein is cleaved by a furin-like protease to its mature M protein form. This allows the formation of E protein homodimers, which are thus “activated” (187). The E protein is the largest structural protein, consisting of nearly 500 amino acids with up to two potential glycosylation sites. It is the major target for the humoral immune response and is thought to be important in viral entry into host cells. Studies with monoclonal antibodies and more recently with x-ray crystallography have determined the composition of the E proteins’ three domains (188,189). Domain III is the putative receptor-binding domain (by which virions attach to the yet-to-be-identified host cell receptor), domain II is the dimerization domain, and domain I has a central beta barrel and is the hinge domain that links the other two domains. Following viral attachment to the cell surface, flaviviruses enter cells by endocytosis. Subsequent fusion of the virus’ lipid membrane with the endosome membrane allows viral RNA to penetrate into the cytoplasm of the infected cell (186). Recent cryoelectron microscopic studies have shown an arrangement of 90 E-protein dimers lying flat on the surface of the virion, which rearrange to form E homodimers as the pH level decreases, exposing an internal fusion peptide and a patch of viral membrane for fusion. Interestingly, recent studies have shown the E1 protein of alphaviruses has a striking similarity to the flavivirus E protein, in terms of structure and function (96). Together, they have been labeled class II fusion peptides (190).
West Nile Virus
Epidemiology
WNV was first isolated from the blood of a febrile woman in the West Nile region of northern Uganda in 1937 (191). It was soon shown to be transmitted between vertebrate hosts (especially birds) by mosquitoes. Sporadic cases and larger outbreaks of febrile disease (West Nile fever) were reported in Africa, the Middle East, and Asia (192). Although meningeal irritation was noted in some patients with West Nile fever, the first cases of encephalitis due to WNV occurred when the virus was given as an experimental (and unsuccessful) treatment for advanced cancer in 1951. The first naturally occurring West Nile encephalitis cases were in the elderly residents of a nursing home in Israel (193). Outbreaks of equine and human meningoencephalitis occurred in southern France during the 1960s, and a subtype of WNV (Kunjin virus) was isolated in Australasia. Since the 1990s, the clinical epidemiology of WNV appears to have changed with increasing frequency and severity of outbreaks, including urban disease. These included an outbreak with nearly 400 confirmed cases in Romania in 1996, nearly 200 cases in the Volgograd region of Russia in 1999 and more than 200 cases in Israel in 2000 (194–197). In 1999, the virus appeared in North America for the first time, with 62 confirmed cases (198,199). It spread across the continent during 2000 and 2001, causing a largest encephalitis outbreak in 2002, with nearly 3,000 cases and 250 deaths (75). WNV is now the leading cause of domestically acquired arboviral disease in the United States of America and has spread throughout Canada, the Caribbean, Colombia, and Mexico (200,201). In 2010, WNV outbreaks occurred in Greece with 262 confirmed human cases with 197 cases of neuroinvasive WNV and in Romania with 57 cases, out of which 54 was neuroinvasive (202,203). Another outbreak occurred in Greece in 2011 with 31 cases of neuroinvasive WNV (204).
Most human infections with WNV are asymptomatic. In the 1998 to 1999 outbreaks, approximately 1 in 5 infections resulted in West Nile fever and only about 1 in 150 developed CNS disease (194,197). Over 75% of patients infected with WNV had neuroinvasive disease (encephalitis, meningitis, or acute flaccid paralysis) during the recent outbreak in Greece and over 94% during the Romanian outbreak (202,203). In contrast, the proportions were much lower in earlier outbreaks in Africa (192,205). In outbreaks across Europe and America, the risk of febrile disease and of neurologic disease increased with age, which may in part explain the differences compared to parts of Africa. In Egypt, most of the population is infected during childhood, and neurologic disease is rare (205). In a South African outbreak of 18,000 people of all ages, only a single encephalitis case was reported (192).
Recent molecular phylogenetic studies show that isolates of WNV can be divided into seven lineages. Lineage 1 has been subdivided into a further three clades: 1a, 1b, and 1c. Lineage 1b has spread to Australasia as Kunjin virus, whereas lineages 1a and 5 are found in India, and lineage 6 in Malaysia (206). Lineage 2 strains have mostly been found in Africa, whereas lineage 1 strains are more widely distributed and are responsible for all the large outbreaks during 1998 to 1999 (207,208). This has led to the suggestion that they may be more virulent, although neuroinvasive strains have been shown in both lineages in animal models (209). However, lineage 2 was more prevalent during the recent outbreaks in Europe (Greece, Romania, and Italy) and therefore may disperse wider in the future (210,211).
In nature, WNV is transmitted in an enzootic cycle between birds by mosquitoes. WNV infects over 300 different bird species and 50 mosquito species (1). Members of the order Passeriformes (jays, blackbirds, finches, warblers, sparrows, and crows) appear to be important in maintenance of the virus in nature (because of viremias); the family Corvidae (crows, blue jays) seems to be particularly susceptible Culex mosquitos, particularly Culex pipiens, appear to be important in the enzootic cycle, although different species may act as “bridging vectors” transmitting the virus to humans.
How WNV is introduced to new areas is not completely understood. Migratory birds are thought to be important for the movement of WNV from Africa into southern Europe. They may have been involved in the virus’ introduction into the United States, although imported exotic birds, a viremic human, or inadvertently transported mosquitoes seem more likely (212). Molecular genetic evidence suggests there was a single introduction into the United States of a strain closely related to one isolated from a goose in Israel (207). A complex interplay of viral, avian, mosquito, human, and climatic factors may contribute to the large outbreaks that have characterized the disease recently (Fig. 15.4). During the 2002 outbreak in the United States, transmission also occurred via transplanted organs, infected blood products, and possibly breast milk (213).
Clinical Features
After an incubation period, which is typically 2 to 6 days but may extend to 14 days, patients with West Nile fever develop a sudden onset of an acute nonspecific flulike illness, characterized by high fever with chills, malaise, headache, backache, arthralgia, myalgia, and retroorbital pain (86). Other nonspecific features include anorexia, nausea, vomiting, diarrhea, cough, and sore throat. In epidemics of West Nile fever, a flushed face, conjunctival injection, and generalized lymphadenopathy were common. A maculopapular or pale roseolar rash was reported in about 50% of patients and was more common in children. In one outbreak, 20% of patients with West Nile fever had hepatomegaly and 10% had splenomegaly (214). Myocarditis, pancreatitis, and hepatitis occur occasionally in WNV infection.
Patients with neurologic disease due to WNV typically have a febrile prodrome lasting 1 to 7 days that may be biphasic, before developing neurologic symptoms. Although in most cases, the prodrome is nonspecific, 15% to 20% of patients may have features suggestive of West Nile fever, including eye pain, facial congestion, or a rash, though less than 5% had lymphadenopathy (215). In the 1998 to 1999 outbreaks, approximately two thirds of hospitalized patients had encephalitis (with or without signs of meningeal irritation), and one third had meningitis (194,196,199). Severe generalized muscle weakness was a common feature in the 1999 New York outbreak and subsequent outbreaks in the United States (199). In some patients, this affects only the limbs, but in others, respiratory and bulbar musculature are affected, requiring ventilation. Though initially ascribed to Guillain-Barré syndrome, the weakness was probably due to anterior horn cell damage (myelitis), as is seen in other flavivirus infections (86). Conscious patients with a polio-like flaccid paralysis due to WNV were recognized in the 1970s and 2002 (70,216). In the recent outbreaks in Greece, 85% of patients had encephalitis/meningoencephalitis and 12% had meningitis, followed by 3% with acute flaccid paralysis (202).
Although seizures occurred in approximately 30% of patients in the early descriptions of West Nile encephalitis, they did not appear to be an important feature in the Romania or the New York outbreak (199). Other neurologic features include cranial neuropathies, optic neuritis, and ataxia. Stiffness, rigidity, spasms, and tremors associated with basal ganglia damage similar to that seen in JE (217) have also recently been recognized in West Nile encephalitis (32).
Overall case-fatality rates for patients hospitalized with West Nile encephalitis outbreaks ranged from 4% to 14% but were higher in older patients (196,199). However, the overall case-fatality rate during the recent Greece outbreak was much higher at 17%, increasing to nearly 35% for those older than 80 years of age (202). Other risk factors for death include the presence of profound weakness, deep coma, failure to produce IgM antibody, impaired immunity, and coexisting illness such as hypertension and diabetes mellitus (199,218). Neurologic sequelae are common among survivors. In one study, half of patients hospitalized still had a deficit at discharge and only 33% recovered fully at 1 year (219).
Diagnosis
Approximately 50% of patients have a peripheral leukocytosis, and 15% have leukopenia (199,219). Hyponatremia sometimes occurs in encephalitic patients. Examination of the CSF typically shows a moderate lymphocytic pleocytosis, although sometimes no cells or neutrophils may predominate. The protein is moderately elevated and the glucose ratio is typically normal. CT scans of the brain are usually normal. MRI may show nonspecific enhancement of the meninges or periventricular areas (199,220) or high signal intensities on T2-weighted images in the thalamus and other basal ganglia (32). Nerve conduction studies typically show reduced motor axonal amplitudes consistent with anterior horn cell damage, although there may also be some slowing of conduction velocities and some changes to sensory nerves (86,216). The differential diagnosis is broad and includes other causes of viral encephalitis (Table 15.3) and other causes of fever and reduced consciousness (Table 15.4).
Attempts at WNV isolation from serum or CSF are usually unsuccessful, because viremias are low, and the virus has cleared by the time most patients present (Fig. 15.3). Techniques include detection of viral antigen by ELISA or of viral nucleic acid using reverse transcriptase PCR (RT-PCR) or real-time PCR (Taq-Man). Real-time PCR, the most sensitive of these techniques, detects only 55% of patients (221). Newer real-time RT-PCR assays, including multiplex RT-PCR assays are more sensitive and offer rapid detection of WNV (81,210,222). The accepted standard for diagnosing WNV infection is the detection of IgM-specific antibodies in CSF and/or serum using IgM capture ELISAs (29). Whereas antibody is detected in the serum of those with West Nile fever or even asymptomatic infection, IgM in the CSF is specific for CNS infection. Half of patients have antibody on admission, and almost all have antibody by the seventh day of admission. Those who do not are more likely to have virus isolated and are more likely to die (32,223).
Treatment and Prevention
There is no established antiviral treatment for West Nile encephalitis, although IFN-α, ribavirin, and human immune globulin have been used in some patients (196). Treatment for patients with West Nile encephalitis is supportive. Mosquito repellents are an identified prophylaxis being particularly important for those in “at-risk” groups, such as the elderly and the immunocompromised. There is no human vaccine for WNV, although a crude formalin-inactivated vaccine and a recombinant plasmidic DNA vaccine has been developed for horses (224,225). Several new vaccine candidates for human are being developed and evaluated with some vaccines in phase I/II human trials (210,226,227).
Japanese Encephalitis
Epidemiology
Outbreaks of encephalitis have been described in Japan since the 1870s (228). The virus was first isolated in 1935 and has been recognized across much of eastern and southern Asia since then. All of Southeast Asia, the western Pacific region, most of the Asian subcontinent, and much of southern China is now affected, and the virus recently reached Australia for the first time (229). An estimated 35,000 to 50,000 cases and 10,000 deaths occur annually, making JEV numerically the most important cause of epidemic viral encephalitis worldwide (230). Approximately half the survivors have severe neuropsychiatric sequelae, imposing a large socioeconomic burden in the areas affected. JEV is transmitted naturally in an enzootic cycle between birds, pigs, and other vertebrate hosts by mosquitoes, especially Culex tritaeniorhynchus, Culex gelidus, and other species that breed in rice paddies. Humans become infected when they encroach upon this enzootic cycle. Because the virus is so ubiquitous, in rural areas almost all humans become infected during childhood, but only a small proportion, estimated at around 1 in 300 develop symptoms (230), which may range from a nonspecific febrile illness through to a severe meningoencephalomyelitis. In endemic areas, most cases of JEV occur in children because by the time they reach adulthood, almost all individuals have been exposed to the virus and will have developed neutralizing antibodies. However, when immunologically naive adults are exposed to the virus, for example, when the virus moves to new geographical areas or when travelers or service personnel visit Asia, they too may develop disease (231). In northern temperate parts of Asia, JEV causes large summer epidemics, but in southern tropical areas, disease is year round, with a peak in the summer months (232). There are at least four genotypes of JEV across Asia; molecular phylogenetic studies suggest that the distribution of genotypes is best explained by the virus’ origin in the Indonesia-Malaysia region and spread from here (233–235). A recent molecular phylogenetic study has identified the Muar strain of JEV as the fifth genotype of JEV with approximately 20% divergence from other JEV strains (236). Furthermore, recently isolated strains from C. tritaeniorhynchus in China and from Culex bitaeniorhynchus in Republic of Korea have been identified as genotype V, suggesting that this genotype may be reemerging in Asia (237,238).
Clinical Features
After a 4- to 14-day incubation period, most patients develop a brief nonspecific febrile illness and then neurologic disease, manifesting as a reduction in the level of consciousness and seizures. Seizures occur in approximately 85% of children and 10% of adults with JEV (68,239). Multiple seizures and status epilepticus are associated with a poor outcome. Subtle motor status epilepticus, in which the only clinical manifestation might be the twitching of a finger or eyebrow, is important in JEV (68). Multiple uncontrolled seizures may be associated with increased ICP and clinical signs of brainstem herniation syndromes (68). Movement disorders are common in JEV, both in the acute stages of infection and as part of the spectrum of neuropsychiatric sequelae. One quarter of patients showed acute manifestations in one series (68). A characteristic parkinsonian syndrome includes masklike facies, tremors, and cogwheel rigidity. Other movement disorders include generalized rigidity, jaw dystonias, opisthotonus, choreoathetosis, orofacial dyskinesias (involuntary tongue protrusions), myoclonic jerks, and opsoclonus myoclonus (68,217). These disorders are thought to be the clinical correlate of the inflammation often seen in the basal ganglia—particularly the thalamus and substantia nigra—on MRI and at autopsy (217,240). In some patients, intention tremors and ataxia reflect cerebellar involvement. Other focal neurologic signs include cranial nerve palsies, upper motor neuron weakness (in 30% to 50% of patients), and flaccid limb weakness, with reduced or absent reflexes, which is often associated with respiratory or bulbar paralysis (241). The combination of upper and lower motor neuron damage can lead to bizarre mixtures of clinical signs that can change hourly during the acute stages of infection. In addition to causing flaccid weakness in comatose patients with encephalitis, JEV can cause a poliomyelitis-like acute flaccid paralysis in fully conscious patients (69). Acute retention of urine, due to an atonic bladder, may be an early clue that paralysis is due to a flavivirus (69). Overall, 20% to 30% of hospitalized patients die, and half the survivors have neuropsychiatric sequelae. Poor prognostic signs include a depressed level of consciousness, decerebrate posturing, multiple seizures, increased ICP, isolation of virus from the CSF, and low levels of JEV-specific IgM and IgG in CSF and serum (31,68,239,242). Other nonspecific indicators include elevated admission temperature, absent abdominal reflexes, hyponatremia, low serum iron level, and elevated CSF white blood cell counts and protein level (68,126,239,243,244).
Diagnosis
A peripheral polymorphonuclear leukocytosis is common. CSF examination reveals an elevated opening pressure in 50% of patients and usually a lymphocytic pleocytosis with a normal glucose ratio and slightly elevated protein. MRI may show high signal intensity on T2-weighted scans in the thalamus, other basal ganglia, midbrain, brainstem, and sometimes anterior spinal cord. EEGs may reveal seizure activity, including periodic lateralized epileptiform discharges (PLEDs) as occurs with HSV encephalitis. This is usually on a background of slow-wave activity. Nerve conduction studies typically show reduced motor amplitudes, consistent with damage to the lower motor neurons in the anterior horns of the spinal cord (69,241), as is seen at autopsy (240). JEV is confirmed by IgM and IgG capture ELISAs, revealing antibody in the serum and the CSF (27,245,246). A robust and userfriendly rapid IgM capture ELISA (JEV Chex) has been developed with similar sensitivity as conventional ELISAs (247). Virus isolation and PCR from serum are usually negative; they may be positive in the CSF of fatal cases and in postmortem brain tissue (31,248).
Treatment and Prevention
A number of antiviral compounds against JEV have shown promise in vitro or animal models, including nitric oxide, ribavirin, and IFN-α (249–251). IFN-α showed promise in open clinical trials (252), but in a randomized placebo-controlled trial in Vietnamese children, it failed to make any difference to the outcome (82). Treatment of JEV focuses on controlling the complications of infection such as seizures and ICP. High-dose dexamethasone failed to show any benefit (89). Recent studies on mice have shown protective effects of pentoxifylline and minocycline against JEV challenge (253–255).
Given that the vectors of JEV breed in rice paddies, vector control may seem an impossible task, but measures that may have an impact include intermittent irrigation of the rice paddies and use of natural larvicides, such as larvivorous fish and the plant neem (Azadirachta indica) (256). Personal protection with insect repellents and by using mosquito netting is also recommended. However, the most effective prevention is with vaccines. A mouse-brain–derived formalin-inactivated vaccine (JE-Vax) has been available for many years, produced by the Japanese under the Biken label and by the Korean Green Cross. Efficacy was demonstrated in a double-blind trial in Thailand (257), and it is used by travelers and service personnel and in some of the wealthier Asian countries (231). Earlier crude preparations of the vaccine were associated with adverse events, and in the early 1990s, there were reports of hypersensitivity reactions, although the risk of serious neurologic adverse events is low, at about 1 in 1 million (258). JE-Vax is no longer manufactured and all existing stocks expired in May 2011 (259). A live attenuated vaccine (SA14-14-2), developed by passage through primary hamster kidney cells, has been used in China since the 1980s and was shown to be safe and efficacious (260–262). It is also relatively cheap and has been licensed to use in Korea, Nepal, and Sri Lanka. However, regulatory approval for its wider use has been delayed because of concerns about its production, in particular whether it meets international “good manufacturing practice.” A new inactivated Vero cell culture–derived vaccine (IC51 or IXIARO) using the attenuated SA14-14-2 strain for adults is now approved for use in the United States, Europe, Canada, Australia, Hong Kong, and Switzerland. Clinical trials are ongoing to determine the safety and efficacy of this vaccine for use in children (259). Newer vaccines in clinical trials include a chimeric vaccine (JE-CV or IMOJEV) in which the prM and E genes of JEVSA14-14-2 strain are inserted into the genome of the yellow fever 17D “backbone” containing the yellow fever nonstructural gene, which has been used safely for many years (226,263).
St. Louis Encephalitis
Epidemiology
Before West Nile encephalitis in New York in 1999, St. Louis encephalitis (SLE) was the most important flavivirus in North America. Outbreaks compatible with SLE were described from the 1920s, but the disease was first recognized in Paris, Illinois and then St. Louis and Kansas City, Missouri in the 1930s. The virus was isolated from the brain of a fatal case in 1931 (264) and is transmitted in nature between passeriform and columbiform birds by Culex mosquitoes. The area affected by SLE extends from Canada through the United States to Central and South America. Strains of virus circulating in the United States are genetically distinct from those in Central and South America, forming two major clades, within which there are subgroups. Strains in the western United States, which are transmitted by C. tarsalismosquitoes, differ from those found in the east that are transmitted by C. pipiens/Culex quinquefasciatus and Culex nigripalpus. Eastern strains are associated with greater epidemic potential, being more readily transmitted by mosquitoes, causing higher viremias in sparrows (one of the major vertebrate hosts) and a higher case-fatality rate in humans (265). However, between epidemics in the east, there may be long intervals during which no cases are seen. In contrast, in the western United States, transmission is endemic and sporadic cases are seen every year, but the case-fatality rates are lower. The incidence rates are highest in the Ohio and Mississippi River basins and the Gulf Coast. The annual reported incidence has fluctuated from 0.003 to 0.752 per 100,000, with a median of 35 cases reported each year (265). However, larger numbers have occurred in some years. In 1975, the largest outbreak recorded caused 2,800 cases in 31 states, and in 1990, there were 222 cases during an epidemic in Florida. Serologic surveys suggest that on average approximately 1 in 300 infections is symptomatic. This rises with age, from 1 in 800 among children younger than 10 years to 1 in 85 for adults. Human immunodeficiency virus–positive individuals appear to be at greater risk of acquiring SLE (266). More recently, an outbreak of SLE occurred in Argentina with 47 laboratory-confirmed cases and nine deaths (267,268).
Clinical Features
After an incubation period, which is usually around 4 days but may extend to 21 days, patients present with fever, headache, malaise, myalgias, and other nonspecific features such as diarrhea, nausea, vomiting, cough, and sore throat. Dysuria, urgency, and incontinence are early features in some patients. In patients younger than 20 years, about 55% have encephalitis, and 40% have meningitis, but in those older than 60 years, more than 90% have encephalitis (269). The most common manifestation of encephalitis is a reduced level of consciousness, which may range from mild confusion to deep coma. Tremulousness of the eyelids, tongue, lips, and extremities is one of the most common neurologic signs. More marked involuntary movements such as myoclonus, nystagmus, and opsoclonus are less common. About 25% of patients have cranial nerve palsies, usually unilateral. Cerebellar ataxias are also common. Seizures occur in children and in more severe adult cases and are a poor prognostic sign (270). Subtle motor seizures have also been reported (271). About 17% of patients die (269), and neuropsychiatric sequelae including emotional disturbances, forgetfulness, tremor, unsteadiness, and visual disturbances occur in about 33% of patients.
Diagnosis
The peripheral white blood cell count is normal or slightly elevated. In some patients, microscopic hematuria, proteinuria, and pyuria have been reported. Hyponatremia due to SIADH secretion occurs in more than one third of patients, and alanine aminotransferase and creatinine phosphokinase levels may be slightly elevated. One third of patients have an elevated CSF opening pressure, and there is typically a moderate mononuclear pleocytosis, with an elevated protein level. EEGs show diffuse slowing and occasional spike-and-wave activity, including PLEDs. The MRI may show high signal intensity in the substantia nigra (269). The diagnosis is usually made by IgM capture ELISA or immunofluorescence, with nearly 100% of CSF samples being positive by day 7 of illness (272). Antibody can also be measured in the serum, but there may be problems with cross-reactive antibody in patients previously exposed to other flaviviruses, such as dengue. Virus can sometimes be cultured from the brain tissue of fatal cases or occasionally demonstrated by electron microscopy. Viral antigen detection and PCR results may be positive but are not reliable for routine diagnosis.
Treatment and Prevention
There is no antiviral treatment; thus, care is supportive. There is no vaccine. Measures to reduce the risk of being bitten by an infected mosquito are described earlier in this chapter.
Murray Valley Encephalitis
Epidemiology
Outbreaks of encephalitis in Australia in 1917 and 1922, labeled “Australian X” disease, or an “aberrant form of poliomyelitis” (273), have subsequently been attributed to MVEV, which was first isolated from the brain of a fatal case in 1951 (274). The virus has been found across parts of Australia and New Guinea and is transmitted between herons, egrets, and other aquatic birds, by Culex annulirostris, and other mosquitoes. The overwintering mechanism and factors responsible for the intermittent epidemics are not known. MVEV is enzootic in the Kimberley region of Western Australia and the Northern Territory and is thought to only reach southeastern Australia during extreme weather conditions (275). Only about 1 in 1,000 to 1 in 2,000 infections result in disease, and the number of cases is small, 25 between 1990 and 1998. Most cases are in aboriginal children living in areas where they are exposed to the virus, but cases have also occurred in travelers to these areas (276). More recently, the number of MVEV cases increased (16 cases and three deaths) in endemic areas of Australia and reemerged in southeastern Australia. This outbreak in 2011 was followed after heavy rainfall and flooding resulting in increased numbers of C. annulirostris mosquitoes and widespread seroconversion among sentinel chicken flocks (277).
Clinical Features, Diagnosis, and Treatment
After a brief nonspecific febrile illness, milder cases develop meningism and tremulousness, whereas in more severe cases, there are seizures, flaccid paralysis requiring mechanical ventilation, and coma (276). Infants may deteriorate rapidly and die within 24 hours. Approximately one fourth of hospitalized cases die and one fourth have severe sequelae. Typically, there is a CSF pleocytosis, with mildly elevated protein and normal glucose levels. MRI may show high signal intensities in the basal ganglia (278). Virus has been isolated by inoculating postmortem brain tissue into chick embryos, but the diagnosis is usually made serologically with an ELISA, hemagglutination inhibition, complement fixation, or neutralization test. Treatment is supportive, because there is no antiviral drug. Patients with MVE have been treated with corticosteroids but the effectiveness has not been assessed in controlled clinical studies (277). No vaccine is available, and the low incidence of disease makes it unlikely that one will be developed. However, recent studies in mice have shown that the live chimeric JEV vaccine offered cross protective immunity against lethal challenge with MVEV (279).
Tick-Borne Encephalitis
Epidemiology
Descriptions of a disease compatible with TBE appeared from the 1930s, and the virus was first isolated by Russian scientists in the Far East in 1937 (280). Three closely related subtypes of TBE virus exist, whose names reflect the geographical areas they principally affect: European/Western, Siberian, and the Far East. However, across this vast geographical area, the disease was given a range of different names (central European encephalitis, Russian spring/summer encephalitis, Far East Russian encephalitis, biphasic milk fever, Taiga encephalitis, Kumlinge disease, Fruhsommer meningoenzephalitis) before it was realized that they are essentially the same disease. The TBE group serocomplex (recently renamed the mammalian group of tick-borne flaviviruses) also includes Powassan virus (a rare cause of encephalitis in Canada); louping ill virus (a very rare cause of CNS disease in the British Isles and Scandinavia); and viruses that cause hemorrhagic disease, such as Kyasanur Forest disease virus (in India) and Omsk hemorrhagic fever virus (in Siberia) (Fig. 15.1). TBE virus is naturally transmitted between small rodents by hard Ixodes ticks (particularly Ixodes ricinus and Ixodes persulcatus). Because ticks may live for months or even years, and because they can pass the virus to their offspring transovarially and transtadially, they act as important reservoirs. Following the bite of an infected tick, small mammals become viremic, and subsequent biting ticks then become infected. In addition to this “classic” arboviral transmission cycle, virus may also be transmitted from tick to tick via infected reticuloendothelial and inflammatory cells (Langerhans cells, neutrophils, monocytes, and macrophages) in the skin of the vertebrate host without the need for the animal to become viremic (8). Adult ticks tend to feed on larger mammals and thus infect humans walking through dense forest between spring and autumn. Across the large geographical area where TBE occurs, the virus tends to circulate in small “natural foci” where the vegetation, temperature, moisture, and presence of appropriate mammalian hosts supports their existence. Humans can also become infected by drinking the unpasteurized milk or cheese of infected goats, cows, and sheep, causing “biphasic milk fever.” There has been a dramatic increase in the number of cases of TBE in humans following drinking TBEV-infected milk in Russia and Europe (281). The incidence of TBE varies according to location and year (282). TBE is endemic in 27 European countries. The endemic area spans from central and Eastern Europe to Siberia and some parts of Asia, including China and Japan. Nearly 170,000 clinical cases of TBE have been reported in Europe and Russia between 1990 and 1999. In Europe, there have been on average about 3,000 cases annually in the last 5 years (281). Following the collapse of the former Soviet Union and reduced use of pesticides and vaccine against TBE, the annual incidence rose to more than 10,000 cases (3). Serologic surveys indicate that in endemic regions, 70% to 95% of infections are subclinical.
Clinical Features
Three fourths of patients recall a tick bite, a median of 8 days (range, 4 to 28 days) before symptoms develop (283). A couple days of headache, fatigue, and pain in the neck, shoulders, and lower back precede the onset of high fever, nausea, and vomiting. In three fourths of patients, the illness is biphasic, with this febrile prodrome of several days, followed by an afebrile period of about 8 days (range, 1 to 33 days) before neurologic disease develops (283,284). In the mildest form of disease—labeled the “febrile form” by Russian clinicians—the febrile phase lasts from 1 to 5 days, sometimes with severe muscle pains and sometimes numbness and fasciculations, before resolving with no residual deficit (3). In the “meningeal form” of disease, there is neck stiffness and photophobia. The “meningoencephalitic form” is characterized by a reduced level of consciousness, which may range from drowsiness and hallucination to deep coma, focal neurologic signs, including hemiplegia, and seizures. There may also be cardiac arrhythmias. A “poliomyelitic form” with poliomyelitis-like flaccid paralysis is common in TBE virus infection. This usually affects the neck and upper limbs to cause pain, sometimes with periodic muscle contractions and numbness, then upper limb weakness with winging of the scapula, wristdrop, or a “hanged head” due to neck extensor weakness. Muscle atrophy begins after the second or third week and persists. In contrast, some patients develop a “polyradiculoneurotic” form of disease: neuropathy occurs 1 to 2 weeks after the initial febrile phase and is associated with a recurrence of fever, but there is usually complete recovery. Finally, in Russia, a “chronic” form of TBE has been described and is believed to be caused only by the Siberian subtype of TBEV. In some patients, deterioration continues long after the acute disease, postmortem examination suggests chronic inflammation, and viral RNA may be detected by nucleic acid hybridization. Other patients are asymptomatic following the initial tick bite but present years later with a progressive form of disease, with virus being isolated at autopsy (65). Spontaneous regular contractions (myoclonic jerks) of the limbs are seen in about 25% of patients with all neurologic forms of TBE disease and may persist as epilepsia partialis continua (Kozhevnikov epilepsy).
Traditionally, disease caused by the Far East subtype of TBE virus is thought to be more severe than that caused by the European subtype, with case-fatality rates of 20% to 60% compared with 1% to 3%, respectively. Differences in criteria for hospitalization may account for much of this apparent difference, although differences in virulence have been found in animal models. The case-fatality rate of the Siberian subtype appears to be similar to that of the European subtype, with neurologic sequelae reported for 30% to 60% of survivors. Interestingly, in biphasic milk fever following oral ingestion of infected milk, TBE virus typically causes only the “febrile form” of disease. Although there is sometimes mild meningism, encephalitis and paralysis are not seen, and recovery is the rule (3).
Diagnosis
During the initial febrile stage, leukopenia and thrombocytopenia are common (285), but by the time patients have neurologic disease, many have a leukocytosis (283). CSF examination usually reveals a mild pleocytosis with elevated protein level. EEGs of patients with encephalitis show slowing with or without focal activity (283). On MRI, abnormalities have been shown in about one fourth of patients with encephalitis, usually in the thalamus but sometimes in the caudate, cerebellum, and brainstem. The diagnosis is usually suspected because of the history of tick bite, although other tick-borne febrile illnesses including borreliosis and ehrlichiosis should be considered. The diagnosis is confirmed by detection of IgM antibodies in CSF and/or serum using an ELISA (286), although during the early viremic phase, virus may also be cultured from the blood. PCR assay have also been shown to be useful in detecting TBEV in the first phase of illness (287).
Treatment and Prevention
There is no antiviral treatment, but an anti-TBE immune globulin has been used for postexposure prophylaxis in those bitten by ticks in areas where the virus circulates. It is licensed under the FSME-Bulin label by Baxter in Austria, and the Encegam label by Chiron/Behringwerke in Germany. An intramuscular dose of 0.2 mL/kg is recommended up to 4 days after the tick bite (288). Prophylaxis later than this is not recommended because of the theoretical potential of antibody aggravating inflammation in patients with established neurologic disease. Postexposure prophylaxis is not recommended for children. The preparations have also been used (at 0.4 mL/kg) as short-term preexposure prophylaxis for those about to visit areas at risk.
A formalin-inactivated vaccine based on an Austrian virus isolate (TBEV-Eu strain Neudoerfl) grown in chick embryo cells has been commercially available in Europe since 1976. It had a relatively high rate of side effects (fever, headache, malaise) but has been replaced by a highly purified form, prepared by ultracentrifugation (289). This vaccine (FMSE-Immun, Baxter), which contains aluminum hydroxide as an adjuvant, has an efficacy of about 98%. Vaccination is recommended for those living, traveling, or working in areas at risk, as well as laboratory workers. Mass vaccination since 1981 in Austria resulted in a marked decline in the number of TBE cases (290). Another formalin-inactivated vaccine, based on the TBEV-Eu strain K23 (Encepur, Novartis) manufactured in Germany is also used in Europe. This vaccine was initially withdrawn from pediatric use because of allergic reactions related to polygelin, which was removed in 2001 (291). Children are given half the adult dose to reduce the high fever that was observed when given the full dose (292). Two other formalin-inactivated vaccines, TBE-Moscow vaccine (based on the Far-Eastern Sofjin strain) and EnceVir vaccine (based on the Far-Eastern 205 strain), are widely used in Russia and several Asian countries. EnceVir is not currently recommended for pediatric use because of high rates of fever and allergic reactions observed in 2010 and 2011. These two vaccines are produced similar to the vaccines used in Europe except the TBE-Moscow vaccine, which is finally lyophilized. All four vaccines are produced according to the World Health Organization (WHO) manufacturing standards (293). Live attenuated vaccines against TBEV are currently under development (294). In 2011, the WHO published its first position paper on TBE vaccines, giving recommendation for TBE vaccination (295).
Neurologic Dengue Disease
Epidemiology
Most patients affected by one of the four dengue viruses (dengue 1, 2, 3, and 4) present with a fever-arthralgia-rash syndrome or a viral hemorrhagic fever (296). The cause and even existence of neurologic manifestations of dengue has been a long-standing controversy (297–302). However, more recent studies have given strong evidence to support neuroinvasion of DENV (303–306). Most authorities now accept that dengue viruses can cause a nonspecific encephalopathy and occasionally encephalitis, even if the mechanism is not yet clear (307,308). The four types of dengue virus were isolated from febrile patients in the 1940s, and dengue is unusual among arboviruses in that humans are the main natural host, although a sylvatic cycle exists in primates in Southeast Asia and West Africa (309). The virus is transmitted between humans by A. aegypti and A. albopictus mosquitoes that breed in small collections of fresh water around the home (e.g., collected in rubbish, water containers, and tires). Dengue is very widely distributed, being found in almost every country between the tropics of Capricorn and Cancer (310). According to the WHO, over 50 million cases of dengue occur every year. Three outbreaks of dengue occurred during 2001 and 2011 in the United States, and the reemergence of autochthonous dengue transmission within Europe has also been described (311,312). Neurologic disease has been reported from virtually every country where dengue occurs (297). It is now recognized that in parts of Southeast Asia, dengue is responsible for 1 in 20 patients admitted with a suspected CNS infection (300) and as many as 1 in 5 of those with a clinical diagnosis of encephalitis (299).
Clinical Features
Most patients with neurologic dengue present with a reduced level of consciousness and other signs of severe dengue infection, including the shock, vascular leakage, and hemorrhage that characterize dengue hemorrhagic fever (DHF). They may also have metabolic disturbances such as hyponatremia and acidosis, and in many patients, the encephalopathy is thought to be secondary to these complications. However, in other patients with no rash, hemorrhage, or other signs of dengue fever or DHF, viral invasion across the BBB causing encephalitis is thought to occur. In support of this is virus isolation, PCR detection, and detection of anti-dengue IgM antibody in the CSF of some patients (300,313–315). A recent study on 150 CSF samples from fatal cases during a dengue epidemic period in Brazil found evidence of DENV in 41 CSF samples out of 84 dengue-positive patients (306). Clinically, these patients present with a brief febrile illness followed by a reduction in consciousness level, which may range from lethargy, drowsiness, and irritability to deep coma. Seizures are also common, particularly in young children (316,317). These may be simple febrile seizures or those associated with prolonged coma. Pyramidal or long tract signs also occur, but the extrapyramidal tremors and tone abnormalities that characterize other arboviral encephalitides such as JEV and West Nile encephalitis (86) are less common in dengue, although they have been described (318,319). Presentations consistent with acute disseminated encephalomyelitis have also been described, some time after a dengue infection (320). Meningismus occurs in up to 30% of patients, usually as part of an encephalopathic illness. Uncomplicated viral meningitis due to dengue viruses is rare. Other neurologic manifestations include mononeuropathies, polyradiculopathies, Guillain-Barré syndrome, and acute neuromuscular weakness due to myositis and hypokalemia (303,307,321,322).
Diagnosis
Patients with dengue often have leukopenia and thrombocytopenia, as well as mildly elevated hepatitic transaminases. In patients with DHF, an elevated hematocrit is found because of fluid loss from blood vessels due to increased vascular permeability (301,323). Hyponatremia is common, particularly once fluid resuscitation has begun. CSF examination reveals a moderate lymphocytic pleocytosis in up to 30% of patients with neurologic disease. CT and MRI may show diffuse cerebral edema, although focal abnormalities have also been reported (300,313,319,324). Dengue can be confirmed by isolating the virus from serum or CSF, PCR detection, or demonstrating IgM antibodies. Because dengue is so common in many parts of the world, and because IgM antibody may persist in the blood for up to 3 months, confirmation of antibody or virus in the CSF provides stronger evidence that dengue was the cause of the neurologic symptoms (307). In addition, rigorous efforts must be made to rule out other causes.
Treatment and Prevention
No effective drugs against dengue are available. Because patients with DHF are particularly likely to develop shock, fluid management is critical, and detailed guidelines are available (325). No vaccines are available yet, but several vaccine candidates are currently undergoing preclinical development and some in clinical trials (326,327). Currently, the most advanced dengue vaccine in phase III clinical trials is ChimeriVax, the chimeric tetravalent live vaccine (yellow fever 17D backbone) manufactured by Sanofi Pasteur (226). Several other chimeric and live attenuated vaccines are also in clinical trials (326,328,329). There is no important enzootic cycle, and because the disease is spread by peridomestic mosquitoes, vector control measures can have an impact. These include educating people to remove Aedes breeding sites, treating stored water with larvicide (e.g., temephos), or the copepod Mesocyclops that feeds on A. aegypti larvae, covering water storage containers, and ultralow volume spraying of organophosphorus insecticides during epidemics (330). In some settings, legislation and fines for those who fail to remove Aedes breeding sites from the home have been effective. Personal protection with insect repellents is also recommended. The evidence for the efficacy of these measures is variable. The only undoubtedly effective vector control measure was the near eradication of A. aegypti from South America, using DDT, during the yellow fever campaign of the 1950s to 1970s. Since that campaign ended, Aedes has reinfested South America (331). Worldwide, A. aegypti continues to spread, and dengue is increasing as a global health problem (332). In 2007, sequencing of the A. aegypti genome was completed and has led to the development of transgenic mosquitoes that could be useful in preventing dengue transmission to humans (333). These include development of sterile mosquitoes, interfering with mosquito feeding and reproduction and the use of Wolbachia to infect mosquitoes (92–94).
BUNYAVIRIDAE
The Bunyaviridae family is the largest family of animal viruses, with more than 350 members. It is named after Bunyamwera Village in Uganda where the prototype virus was isolated. The family consists of five genera, the first two of which contain important arboviral causes of CNS disease. Within each genus of the family, viruses are placed into serogroups according to their cross reactivity in serologic tests.
• The Orthobunyavirus genus contains the mosquito-borne LACV and other members of the California encephalitis serogroup of viruses.
• The Phlebovirus genus includes the sandfly-borne TOSV, which is emerging as an important cause of CNS disease in southern Europe, and RVFV, which is transmitted by mosquitoes and causes febrile, hemorrhagic, and occasional CNS disease.
• The Nairovirus genus includes Crimean-Congo hemorrhagic fever virus, which is transmitted by ticks.
• The Hantavirus genus, whose members are not arthropod borne, includes viruses that cause hantavirus pulmonary syndrome, and hemorrhagic fever with renal syndrome.
• The Tospovirus genus contains only plant viruses transmitted by thrips (woodworm), and no human pathogens.
Infectious Agent
All members of the family Bunyaviridae are 90 to 120 nm in diameter and are spherical in shape, except hantaviruses, which are either spherical or rod-shaped particles. These enveloped viruses have glycoprotein spikes assembled from the glycoproteins Gn and Gc, and enclose three circular nucleocapsids, containing three linear segments of single-stranded negative-sense RNA, designated L (large), M (medium), and S (small) (334,335). These range in size from 1 to 2.2 kb for the S, 3.5 to 6 kb for the M, and 6.3 to 12.0 kb for the L. The L segment codes for a single L protein, RNA-dependent RNA polymerase (RdRp) protein. The M segment codes for surface glycoproteins G1 and G2, and for a nonstructural protein NSm. The S segment codes for nucleocapsid protein N (forms the ribonucleoprotein [RNP] complex by encapsidating the viral RNA replication products) and for a nonstructural protein NSs, although for hantaviruses, the nonstructural proteins NSm and NSs have not been detected (335,336).
Attachment of G1 and/or G2 glycoproteins to an as yet unidentified cell receptor is thought to be the first step in viral replication. However, some studies suggest that integrins are involved in hantavirus attachment, and phebovirus entry into dendritic cells involves DC-SIGN (337,338). Entry into the cell by endocytosis is followed by uncoating and release of the three nucleocapsids into the cytoplasm, possibly mediated by pH-dependent fusion of the viral envelope and host endosomal membrane. A recent study suggests that after clathrin-independent endocytosis, phleboviruses pass through early and late endosomes, followed by late endosomal acidification and release of RNPs and accumulation in the Golgi (339). Replication of viral RNA occurs via a positive-sense complementary RNA (cRNA) intermediate. Transcription of viral RNA to messenger RNA (mRNA) is followed by translation to produce viral proteins. For Phlebovirus and Tospovirus, the SA segment is transcribed in both positive and negative directions (ambisense). The G1 and G2 proteins are glycosylated, and viral particles assemble by budding into the Golgi vesicles. These are transported to the cell surface, and fusion of the cytoplasmic vesicles with the plasma membrane results in virion release through exocytosis. Although this mechanism of viral release applies to most viruses in the family Bunyaviridae, RVFV can also bud off directly at the cell surface.
La Crosse and Other California Serogroup Viruses
The California serogroup viruses are the only major cause of CNS disease in the Bunyavirus.
Epidemiology
California encephalitis virus was isolated from mosquitoes by Reeves and Hammon in 1941 (340) and was shown to be associated with three cases of encephalitis. Although the serogroup was named after this virus, human disease is rare (341). LACV, which was isolated from the brain of a fatal encephalitis case in 1960 (342), is the most important member of the group and was probably the most common cause of arboviral encephalitis in the United States until the arrival of WNV. Other members of the California serogroup include Jamestown Canyon virus, which is also a relatively common cause of CNS disease, and snowshoe hare virus, which is not (Table 15.2). California serogroup viruses are typically transmitted in nature between rodents by Aedes mosquitoes. LACV is transmitted between chipmunks and squirrels by Aedes triseriatus, a forest-dwelling tree-hole breeding mosquito that breeds in rainwater collected in artificial containers in urban settings. Evidence is accumulating that the recently introduced mosquito species A. albopictus may be involved in the emergence of LACV infection (343). During the winter months, the virus overwinters by vertical transmission into Aedes eggs (344). For Jamestown Canyon virus, the white-tailed deer is thought to be an important amplifying host. In Europe and Russia, the California encephalitis virus serogroup Tahyna virus is a cause of fever, respiratory symptoms, and occasionally CNS disease (345,346).
Most encephalitis cases due to California serogroup viruses occur during the summer and early fall, particularly among residents of the Mississippi and Ohio River basins (347); however, 31 states have now reported cases, with 130 cases (116 neuroinvasive cases) reported from 14 states in 2011. Nearly 95% of patients were younger than 18 years of age (348). The recent spread of LACV to Tennessee, North Carolina, and West Virginia has been attributed to invasive mosquitoes including A. albopictus (349). The incidence of LACV encephalitis is estimated at up to 30 per 100,000 in endemic areas (67). Most cases occur in children living close to wooded forests or visiting them for recreation; risk factors include the time spent outdoors and proximity of homes to tree holes (343). Approximately 75 encephalitis cases are reported each year. The ratio of asymptomatic to symptomatic infections is about 1,000:1, and in endemic areas, 20% of the population is seropositive by age 60 years. Jamestown Canyon virus is distributed across the northern United States. Encephalitis due to Jamestown Canyon virus occurs mostly in the elderly. Seroprevalence is 4% to 10% in some areas (350).
Clinical Features
Children with LACV encephalitis typically present with fever, headache, malaise, nausea, and vomiting, which are often accompanied by meningeal signs (67,351–353). Seizures, which often include a focal component, occur in approximately 50% of children, one third of whom have status epilepticus. Half the patients have altered consciousness, and 10% are comatose. Focal neurologic signs include hemiparesis, aphasia, dysarthria, chorea, and in about 10% clinical signs of raised ICP. Poor prognostic indicators include reduced plasma sodium level, increased body temperature, and a Glasgow Coma Scale score of less than 13 out of 15, and possibly increased number of seizures. Although fatalities are rare, approximately 10% of patients have sequelae at hospital discharge. About 20% of those with seizures in the hospital develop epilepsy. Jamestown Canyon virus causes a similar clinical pattern (354).
Diagnosis
A peripheral leukocytosis is common, and although there is usually a CSF lymphocytic pleocytosis up to 600 cells/mm3, an early lymphocytic pleocytosis may be normal. CSF protein is elevated in about 30% of patients, but the glucose level is usually normal. Low sodium level due to SIADH secretion is reported in about 20% of patients. Diagnosis is usually serologic because attempts to isolate virus from CSF or blood are negative, although virus has been isolated from brain tissue.
Treatment and Prevention
There is no antiviral treatment for California serogroup viruses, or indeed any members of the Bunyavirus genus. A recent study investigated the safety and pharmacokinetics of intravenous ribavirin treatment for children with LACV encephalitis, but the results did not support the use of ribavirin for LACV encephalitis (355). Attention should focus on treating the complications of infection, particularly hyponatremia and seizures. There is no vaccine. Preventive measures include environmental measures to decrease breeding sites, for example, removing tree holes, tires, and litter, which provide pools of water favored by Aedes mosquitoes for breeding.
Phleboviruses Causing Central Nervous System Disease
Most members of this genus are transmitted by phlebotomine sandflies, although RVFV, which causes epidemics of febrile illness, and occasional hemorrhagic disease, retinitis, or neurologic disease, across sub-Saharan Africa, is a notable exception, being transmitted principally by Culex mosquitoes.
Sandfly Fever Viruses
A febrile illness associated with sandfly bites was recognized since the early twentieth century. During outbreaks in World War II, Albert Sabin isolated sandfly fever Sicilian virus and sandfly fever Naples virus from U.S. troops (356). Both viruses decreased or disappeared after the 1940s in countries performing insecticide spraying for malaria eradication. More recently, an outbreak occurred among Greek soldiers stationed in Cyprus with 256 out of 581 soldiers infected with sandfly fever Sicilian virus (357). In 1971, TOSV, a new virus antigenically closely related to sandfly fever Naples virus, was isolated in Italy from the sandfly Phlebotomus perniciosus (358,359). It has since emerged as the most important cause of pediatric CNS infections in some parts of Italy, causing up to 80% of cases during the summer (360). Children from rural or semiurban areas are especially vulnerable. TOSV has also been recognized in other Mediterranean countries, including Cyprus, France, Greece, Portugal, Spain, and Turkey (361,362). In affected areas, seroprevalence levels of 10% to 25% have been found (361,363). The virus’s natural cycle has not been fully determined. In particular, although it has been shown that the virus replicates in sandflies and can be passed vertically to offspring via transovarial and transtadial transmission, no natural vertebrate host has yet been identified. However, humans have sufficiently long and high viremias to transmit sandfly viruses to biting sandflies, which contributed to some urban outbreaks.
Clinical Features, Investigation, and Diagnosis
Aseptic meningitis is the most common presentation of TOSV, but encephalitis has also been described (363–367). In one series, all 14 patients had neck stiffness and 3 were encephalopathic, including 1 with repeated seizures (360). Peripheral white blood cell counts are usually normal, and the CSF shows a lymphocytic pleocytosis with normal glucose and mildly elevated protein levels. The outcome is generally good, with no deaths or severe sequelae reported. Enterovirus infections are high on the differential for patients with aseptic meningitis in the summer months, and a duplex PCR has been developed to distinguish between these infections (368). TOSV can be isolated from the serum and CSF by inoculation into suckling mice or cell lines. Because humans have high viremias, virus isolation and PCR from serum and CSF is often successful (369). IgM ELISAs have also been developed (368,370,371).
Treatment and Prevention
There is no established antiviral treatment for TOSV infection or other CNS Phlebovirus infections, although ribavirin may be effective in RVF (250). Widespread use of DDT was effective in controlling sandfly fevers in the past, particularly residual spraying of internal walls in homes where sandflies rest. Although sandflies are small enough to penetrate mosquito netting, impregnated bed nets are a deterrent, and the application of insecticides on the skin is recommended.
Rift Valley Fever Virus
RVF virus was first isolated in 1930, during an investigation of a large epizootic of disease causing abortion and death in sheep. Originally found in the Rift Valley of Kenya, the virus is distributed across sub-Saharan Africa, Egypt, Saudi Arabia, and Yemen (332,372,373). Disease in animals follows the explosive increases in mosquito populations caused by heavy rains or new irrigation projects. Humans become infected by mosquitoes or contact with animal blood or other products. In humans, the virus causes epidemics of febrile illness with hemorrhagic manifestations in about 1% to 2% (2). About 0.5% to 1.0% of patients develop retinal vasculitis or encephalitis as a late sequelae 1 to 4 weeks after the acute illness (374). Encephalitis manifests as headache, meningismus, and clouding of consciousness, sometimes with a recrudescence of fever. In fatal cases, focal necrosis is seen pathologically, which may be due to viral cell damage. However, the late presentation after viral clearance and development of antibodies suggest an immunopathologic process may be responsible, possibly due to a delayed hypersensitivity reaction (375). Because this virus is directly transmissible to humans from the body fluids of livestock, abattoir workers in affected areas should wear protective clothing. There are no human vaccines against phleboviruses, but vaccines are available to protect livestock against RVFV and are the main countermeasure against eliminating the source of human infection (376).
COLTIVIRUSES
The genera of the family Reoviridae include the Rotavirus genus and three genera of arboviruses, Orbivirus, Coltivirus, and the recently designated Seadornavirus. The orbiviruses include animal pathogens such as bluetongue virus and African horse sickness virus, but no important human pathogens, and so are not considered further here. The most important coltivirus is CTFV, which because of similarities in its geographical distribution, vector and symptoms were not distinguished from the rickettsial disease Rocky Mountain spotted fever until the 1930s. Its viral etiology was demonstrated in the 1940s. Eyach virus is a coltivirus isolated from ticks in central Europe, where patients with CNS disease have been shown to have antibodies against the virus (377). Banna virus was isolated from the CSF and blood of patients with encephalitis in China (378,379). It had been classified as a coltivirus, but following genome sequencing, it has been placed with Kadipiro virus in the new genus, Seadornavirus (380,381).
Infectious Agent
Like other Reoviridae, coltiviruses are nonenveloped particles consisting of a double-capsid structure with icosahedral symmetry containing double-stranded RNA. The 29-kb genomes are divided into 12 segments of double-stranded RNA (ranging from 0.3 to 3.7 thousand base pairs), which can undergo resortment (382). Based on comparisons with other Reoviridae, each segment is thought to encode the mRNA for a single gene product, which in the case of VP1 is thought to be the RNA-dependent RNA polymerase.
Epidemiology
CTFV is transmitted between ground squirrels, chipmunks, and other small mammals by Dermacentor andersoni (wood ticks). The geographical distribution of cases is limited by the distribution of the vectors and host to mountainous areas between 4,000 and 10,000 feet in the western United States and Canada (383). CTFV or a closely related virus may be transmitted by Dermacentor variabilis in parts of California. Larval, nymphal, or adult ticks may be infected. The virus persists transtadially between the maturing tick forms but is not passed transovarially (Fig. 15.2). Ticks are infected for life, which may be up to 3 years. The vertebrate hosts usually have subclinical viremias that can last for months or even longer in hibernating animals, possibly providing one means for viral overwintering. Whereas immature ticks feed on small mammals, adults feed on larger mammals, deer, elk, and occasionally humans. Human cases of CTF occur in the summer months, when the number of ticks and vertebrate hosts is increased, as is human exposure to the ticks, because of recreational and occupational activities.
Pathogenesis and Clinical Features
CTFV infects hematopoietic cells, resulting in persisting infection of erythrocytes, leukopenia, and thrombocytopenia (384). The relative contributions of viral cytopathology and the host immune response in the pancytopenia is not certain (385). Because CTF is rarely fatal, there are few reports of the pathology, but hyaline membrane disease, endothelial swelling, and focal necrosis of the brain, liver, and spleen have been reported, similar to the changes seen in animal models (386). IFN-α levels in the plasma are high during the first 10 days of infection. After this neutralizing antibody, titers raise, but despite this, viremias persist in nearly half the patients (383).
Transplacental transmission has been recorded, but most patients present with a history of exposure to ticks in an area where the virus circulates, and many will recall a tick attachment. Following 3 to 5 days of incubation (range, 1 to 14 days), there is fever, headache, malaise, and gastrointestinal disturbances. After 2 to 3 days, the fever may subside for a couple of days, before recurring, illustrating the biphasic or “saddleback” fever pattern (50% of patients with CTF). There is sometimes mild conjunctivitis, lymphadenopathy, and a faint maculopapular rash, or petechiae (383). Neurologic features include neck stiffness, photophobia, and mildly reduced consciousness. Rarely, there is encephalitis hepatitis, perimyocarditis, and pneumonitis. Intravascular coagulopathy has been reported; only three deaths, all in children, are noted (387).
Diagnosis
Moderate leukopenia with a relative lymphocytosis and a “left shift” have been reported along with thrombocytopenia, anemia, and elevated liver transaminase and creatinine phosphokinase levels (383). In the CSF, a moderate lymphocytic pleocytosis (up to 500 cells/mm3) is described with normal or slightly elevated protein and reduced glucose. The differential diagnosis includes other tick-borne conditions, including Rocky Mountain spotted fever, ehrlichiosis, tularemia, and Lyme disease. The diagnosis of CTF is confirmed by virus isolation from blood clots or red blood cells, direct immunofluorescence of blood smears to detect antigen in erythrocytes, or antibody detection using ELISAs or neutralization assays.
Treatment and Prevention
There is no established antiviral treatment, although ribavirin has activity in vitro and in the mouse model (388). Treatment is symptomatic; aspirin and other nonsteroidal antiinflammatory drugs should be avoided because of antiplatelet effects. To avoid infection, standard methods to reduce the chances of tick bites should be used, including wearing long-sleeved shirts and trousers, using repellents containing DEET, and frequently inspecting for attached ticks.
ACKNOWLEDGMENTS
Some of the work on flaviviruses described in this chapter was supported by the Wellcome Trust and the Medical Research Council of Great Britain. T.S. is a professor of Neurology. A.P. is an NC3Rs David Sainsbury Fellow. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract (NO1-AI-65306, NO1-AI-15113, NO1-AI-62554, NO1-AI-30025), the General Research Unit (RR-032), and the State of Alabama.
References
1. Hollidge BS, Gonzalez-Scarano F, Soldan SS. Arboviral encephalitides: transmission, emergence, and pathogenesis. J Neuroimmune Pharmacol. 2010;5:428–442.
2. Solomon T. Viral haemorrhagic fevers. In: Cook G, Zumlar A, eds. Manson’s Tropical Diseases. London: Saunders; 2002:773–793.
3. Gritsun TS, Lashkevich VA, Gould EA. Tick-borne encephalitis. Antiviral Res. 2003;57:129–146.
4. Centers for Disease Control and Prevention. West Nile virus infection in organ donor and transplant recipients—Georgia and Florida, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:790.
5. Griffin D. Arboviruses and the central nervous system. Semin Immunopathol. 1995;17:121–132.
6. Johnston LJ, Halliday GM, King NJ. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. J Invest Dermatol. 2000;114:560–568.
7. Wu SJ, Grouard-Vogel G, Sun W, et al. Human skin Langerhans cells are targets of dengue virus infection. Nat Med. 2000;6:816–820.
8. Labuda M, Austyn JM, Zuffova E, et al. Importance of localized skin infection in tick-borne encephalitis virus transmission. Virology. 1996;219:357–366.
9. Lim PY, Behr MJ, Chadwick CM, et al. Keratinocytes are cell targets of West Nile virus in vivo. J Virol. 2011;85:5197–5201.
10. Lustig S, Halevy M, Ben-Nathan D, et al. The role of host immunocompetence in neuroinvasion of Sindbis virus. Arch Virol. 1999;144:1159–1171.
11. Griffin DE. Alphaviruses. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2001:917–962.
12. Hollidge BS, Weiss SR, Soldan SS. The role of interferon antagonist, non-structural proteins in the pathogenesis and emergence of arboviruses. Viruses. 2011;3:629–658.
13. Johnson RT. Virus invasion of the nervous system: a study of sindbis virus infection in the mouse using fluorescent antibody. Am J Pathol. 1965;46:929–931.
14. Johnson RT, Mimms CA. Pathogenesis of viral infections of the central nervous system. N Engl J Med. 1968;278:23–25.
15. Liu C, Voth DW, Rodina P, et al. A comparative study of the pathogenesis of western equine and eastern equine encephalomyelitis viral infections in mice by intracerebral and subcutaneous inoculations. J Infect Dis. 1970;122:53–63.
16. Monath TP, Cropp CP, Harrison AK. Mode of entry of a neurotropic virus into the central nervous system. Reinvestigation of an old controversy. Lab Invest. 1983;48:399–410.
17. Diamond MS, Klein RS. West Nile virus: crossing the blood-brain barrier. Nat Med. 2004;10:1294–1295.
18. Olsen AL, Morrey JD, Smee DF, et al. Correlation between breakdown of the blood–brain barrier and disease outcome of viral encephalitis in mice. Antiviral Res. 2007;75:104–112.
19. Liu TH, Liang LC, Wang CC, et al. The blood-brain barrier in the cerebrum is the initial site for the Japanese encephalitis virus entering the central nervous system. J Neurovirol. 2008;14:514–521.
20. Roe K, Kumar M, Lum S, et al. West Nile virus-induced disruption of the blood–brain barrier in mice is characterized by the degradation of the junctional complex proteins and increase in multiple matrix metalloproteinases. J Gen Virol. 2012;93:1193–1203.
21. Griffin DE, Levine B, Tyor WR, et al. The immune response in viral encephalitis. Semin Immunol. 1992;4:111–119.
22. Landis H, Simon-Jodicke A, Kloti A, et al. Human MxA protein confers resistance to Semliki Forest virus and inhibits the amplification of a Semliki Forest virus-based replicon in the absence of viral structural proteins. J Virol. 1998;72:1516–1522.
23. Klimstra WB, Ryman KD, Bernard KA, et al. Infection of neonatal mice with sindbis virus results in a systemic inflammatory response syndrome. J Virol. 1999;73:10387–10398.
24. Burke DS, Morill JC. Levels of interferon in the plasma and cerebrospinal fluid of patients with acute Japanese encephalitis. J Infect Dis. 1987;155:797–799.
25. Ravi V, Parida S, Desai A, et al. Correlation of tumor necrosis factor levels in the serum and cerebrospinal fluid with clinical outcome in Japanese encephalitis patients. J Med Virol. 1997;51:132–136.
26. Winter PM, Dung NM, Loan HT, et al. Proinflammatory cytokines and chemokines in humans with Japanese encephalitis. J Infect Dis. 2004;190:1618–1626.
27. Burke DS, Nisalak A, Ussery MA, et al. Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J Infect Dis. 1985;151:1093–1099.
28. Tardei G, Ruta S, Chitu V, et al. Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile virus infection. J Clin Microbiol. 2000;38:2232–2239.
29. Martin DA, Biggerstaff BJ, Allen B, et al. Use of immunoglobulin M cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States. Clin Diagn Lab Immunol. 2002;9:544–549.
30. Calisher CH, Berardi VP, Muth DJ, et al. Specificity of immunoglobulin M and G antibody responses in humans infected with eastern and western equine encephalitis viruses: application to rapid serodiagnosis. J Clin Microbiol. 1986;23:369–372.
31. Burke DS, Lorsomrudee W, Leake CJ, et al. Fatal outcome in Japanese encephalitis. Am J Trop Med Hyg. 1985;34:1203–1210.
32. Solomon T, Fisher AF, Beasley DWC, et al. Natural and nosocomial infection in a patient with West Nile encephalitis and extrapyramidal movement disorders. Clin Infect Dis. 2003;36:E140–E145.
33. Griffin D, Levine B, Tyor W, et al. The role of antibody in recovery from alphavirus encephalitis. Immunol Rev. 1997;159:155–161.
34. Després P, Griffin JW, Griffin DE. Effects of anti-E2 monoclonal antibody on sindbis virus replication in AT3 cells expressing bcl-2. J Virol. 1995;69:7006–7014.
35. Tyor WR, Moench TR, Griffin DE. Characterization of B cells and IA expression in Sindbis virus encephalitis. Ann N Y Acad Sci. 1988;540: 491–492.
36. Linn ML, Mateo L, Gardner J, et al. Alphavirus-specific cytotoxic T lymphocytes recognize a cross-reactive epitope from the capsid protein and can eliminate virus from persistently infected macrophages. J Virol. 1998;72:5146–5153.
37. Diamond MS, Shrestha B, Marri A, et al. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol. 2003;77:2578–2586.
38. Heinz FX, Berger R, Tuma W, et al. A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies. Virology. 1983;126:525–537.
39. Kaufman BM, Summers PL, Dubois DR, et al. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg. 1989;41:576–580.
40. Larena M, Regner M, Lee E, et al. Pivotal role of antibody and subsidiary contribution of CD8+ T cells to recovery from infection in a murine model of japanese encephalitis. J Virol. 2011;85:5446–5455.
41. Charlier N, Leyssen P, Paeshuyse J, et al. Infection of SCID mice with Montana Myotis leukoencephalitis virus as a model for flavivirus encephalitis. J Gen Virol. 2002;83:1887–1896.
42. Halevy M, Akov Y, Ben-Nathan D, et al. Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice. Arch Virol. 1994;137:355–370.
43. Biswas SM, Ayachit VM, Sapkal GN, et al. Japanese encephalitis virus produces a CD4+ Th2 response and associated immunoprotection in an adoptive-transfer murine model. J Gen Virol. 2009;90:818–826.
44. Sitati EM, Diamond MS. CD4+ T-Cell responses are required for clearance of West Nile Virus from the central nervous system. J Virol. 2006;80:12060–12069.
45. Shrestha B, Diamond MS. Role of CD8+ T cells in control of West Nile virus infection. J Virol. 2004;78:8312–8321.
46. Shrestha B, Samuel MA, Diamond MS. CD8+ T Cells Require Perforin To Clear West Nile Virus from Infected Neurons. J Virol. 2006;80:119–129.
47. Wang Y, Lobigs M, Lee E, et al. CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol. 2003;77:13323–13334.
48. Wang Y, Lobigs M, Lee E, et al. Exocytosis and Fas mediated cytolytic mechanisms exert protection from West Nile virus induced encephalitis in mice. Immunol Cell Biol. 2004;82:170–173.
49. Licon Luna RM, Lee E, Müllbacher A, et al. Lack of both Fas ligand and perforin protects from flavivirus-mediated encephalitis in mice. J Virol. 2002;76:3202–3211.
50. Johnson RT, Burke DS, Elwell M, et al. Japanese encephalitis: immunocytochemical studies of viral antigen and inflammatory cells in fatal cases. Ann Neurol. 1985;18:567–573.
51. Miyake M. The pathology of Japanese encephalitis. Bull World Health Organ. 1964;30:153–160.
52. Sampson BA, Ambrosi C, Charlot A, et al. The pathology of human West Nile Virus infection. Hum Pathol. 2000;31:527–531.
53. Shieh WJ, Guarner J, Layton M, et al. The role of pathology in an investigation of an outbreak of West Nile encephalitis in New York, 1999. Emerg Infect Dis. 2000;6:370–372.
54. Kalfayan B. Pathology of La Crosse virus infection in humans. Prog Clin Biol Res. 1983;123:179–186.
55. Bastian FO, Wende RD, Singer DB, et al. Eastern equine encephalomyelitis. Histopathologic and ultrastructural changes with isolation of the virus in a human case. Am J Clin Pathol. 1975;64:10–13.
56. Rozdilsky B, Robertson HE, Chorney J. Western encephalitis: report of eight fatal cases. Saskatchewan epidemic, 1965. Can Med Assoc J. 1968;98:79–86.
57. Moench TR, Griffin DE. Immunocytochemical identification and quantitation of the mononuclear cells in the cerebrospinal fluid, meninges, and brain during acute viral meningoencephalitis. J Exp Med. 1984;159:77–88.
58. Griffin DE, Levine B, Ubol S, et al. The effects of alphavirus infection on neurons. Ann Neurol. 1994;35(suppl):S23–S27.
59. Garen PD, Tsai TF, Powers JM. Human eastern equine encephalitis: immunohistochemistry and ultrastructure. Mod Pathol. 1999;12:646–652.
60. Fazakerley JK. Pathogenesis of Semliki Forest virus encephalitis. J Neurovirol. 2002;8(suppl 2):66–74.
61. Murphy FA, Whitfield SG. Eastern equine encephalitis virus infection: electron microscopic studies of mouse central nervous system. Exp Mol Pathol. 1970;13:131–146.
62. Tyor WR, Wesselingh S, Levine B, et al. Long term intraparenchymal Ig secretion after acute viral encephalitis in mice. J Immunol. 1992;149:4016–4020.
63. Lewallen S, White VA, Whitten RO, et al. Clinical-histopathological correlation of the abnormal retinal vessels in cerebral malaria. Arch Ophthalmol. 2000;118:924–928.
64. Noran HH. Chronic equine encephalitis. Am J Pathol. 1944;20:259–267.
65. Gritsun TS, Frolova TV, Zhankov AI, et al. Characterization of a siberian virus isolated from a patient with progressive chronic tick-borne encephalitis. J Virol. 2003;77:25–36.
66. Tesh RB, Siirin M, Guzman H, et al. Persistent West Nile Virus infection in the golden hamster: studies on its mechanism and possible implications for other flavivirus infections. J Infect Dis. 2005;192:287–295.
67. McJunkin JE, de los Reyes EC, Irazuzta JE, et al. La Crosse encephalitis in children. N Engl J Med. 2001;344:801–807.
68. Solomon T, Dung NM, Kneen R, et al. Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis. Brain. 2002;125:1084–1093.
69. Solomon T, Kneen R, Dung NM, et al. Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet. 1998;351:1094–1097.
70. Gadoth N, Weitzman S, Lehmann EE. Acute anterior myelitis complicating West Nile fever. Arch Neurol. 1979;36:172–173.
71. Schellinger PD, Schmutzhard E, Fiebach JB, et al. Poliomyelitic-like illness in central European encephalitis. Neurology. 2000;55:299–302.
72. Kneen R, Solomon T, Appleton R. The role of lumbar puncture in suspected CNS infection—a disappearing skill? Arch Dis Child. 2002;87:181–183.
73. White NJ. Lumbar puncture in cerebral malaria (letter). Lancet. 1991;338:640–641.
74. Solomon T. Flavivirus encephalitis. N Engl J Med. 2004;351:370–378.
75. Solomon T, Ooi MH, Beasley DWC, et al. West Nile encephalitis. BMJ. 2003;326:865–869.
76. Sambol AR, Hinrichs SH, Hogrefe WR, et al. Performance of a commercial immunoglobulin M antibody capture assay using analyte-specific reagents to screen for interfering factors during a West Nile virus epidemic season in Nebraska. Clin Vaccine Immunol. 2007;14:87–89.
77. Johnson AJ, Noga AJ, Kosoy O, et al. Duplex microsphere-based immunoassay for detection of anti-west nile virus and anti-St. Louis encephalitis virus immunoglobulin M antibodies. Clin Diagn Lab Immunol. 2005;12:566–574.
78. Taketa-Graham M, Powell-Pereira JL, Baylis E, et al. High throughput quantitative colorimetric microneutralization assay for the confirmation and differentiation of West Nile Virus and St. Louis encephalitis virus. Am J Trop Med Hyg. 2010:82;501–504.
79. Teles FSRR. Biosensors and rapid diagnostic tests on the frontier between analytical and clinical chemistry for biomolecular diagnosis of dengue disease: a review. Analytica Chimica Acta. 2011;687:28–42.
80. Lee Y-F, Lien K-Y, Lei H-Y, et al. An integrated microfluidic system for rapid diagnosis of dengue virus infection. Biosens Bioelectron. 2009;25:745–752.
81. Naze F, Le Roux K, Schuffenecker I, et al. Simultaneous detection and quantitation of Chikungunya, dengue and West Nile viruses by multiplex RT-PCR assays and dengue virus typing using high resolution melting. J Virol Methods. 2009;162:1–7.
82. Solomon T, Dung NM, Wills B, et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet. 2003;361:821–826.
83. Appleton R, Choonara I, Martland T, et al. The treatment of convulsive status epilepticus in children. The Status Epilepticus Working Party, Members of the Status Epilepticus Working Party. Arch Dis Child. 2000;83:415–419.
84. Kirkham FJ. Non-traumatic coma in children. Arch Dis Child. 2001;85:303–312.
85. Crawley J, Waruiru C, Mithwani S, et al. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study. Lancet. 2000;355:701–706.
86. Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. In: Mackenzie JS, Barrett AD, Deubel V. eds. Current Topics in Microbiology and Immunology: Japanese Encephalitis and West Nile Virus Infections. Berlin: Springer-Verlag; 2002:171–194.
87. Plum F, Posner JB. The pathologic physiology of signs and symptoms of coma. In: Plum F, Posner JB, eds. The Diagnosis of Stupor and Coma. Philadelphia: F. A. Davis Co.; 1982:1–73.
88. Newton CRJC, Crawley J, Sowumni A, et al. Intracranial hypertension in Africans with cerebral malaria. Arch Dis Child. 1997;76:219–226.
89. Hoke CH, Vaughn DW, Nisalak A, et al. Effect of high dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus. J Infect Dis. 1992;165:631–637.
90. Solomon T, Felix JM, Samuel M, et al. Hypoglycaemia in paediatric admissions in Mozambique. Lancet. 1994;343:149–150.
91. Oliva CF, Jacquet M, Gilles J, et al. The sterile insect technique for controlling populations of Aedes albopictus (diptera: culicidae) on Reunion island: mating vigour of sterilized males. PLoS ONE. 2012;7:e49414.
92. Fu G, Lees RS, Nimmo D, et al. Female-specific flightless phenotype for mosquito control. Proc Natl Acad Sci U S A. 2010;107:4550–4554.
93. Hoffmann AA, Montgomery BL, Popovici J, et al. Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature. 2011;476:454–457.
94. Caragata EP, Walker T. Using bacteria to treat diseases. Expert Opin Biol Ther. 2012;12:701–712.
95. Weaver SC, Kang W, Shirako Y, et al. Recombinational history and molecular evolution of western equine encephalomyelitis complex alphaviruses. J Virol. 1997;71:613–623.
96. Lescar J, Roussel A, Wien MW, et al. The Fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell. 2001;105:137–148.
97. TenBroeck C, Merrill MH. A serological difference between eastern and western equine encephalomyelitis virus. Proc Soc Exp Biol Med. 1933;31:217–220.
98. Beckwith WH, Sirpenski S, French RA, et al. Isolation of eastern equine encephalitis virus and West Nile virus from crows during increased arbovirus surveillance in Connecticut, 2000. Am J Trop Med Hyg. 2002;66:422–426.
99. Day JF, Stark LM. Eastern equine encephalitis transmission to emus (Dromaius novaehollandiae) in Volusia County, Florida: 1992 through 1994. J Am Mosq Control Assoc. 1996;12:429–436.
100. Goldfield M, Welsh JN, Taylor BF. The 1959 outbreak of Eastern encephalitis in New Jersey. 5. The inapparent infection:disease ratio. Am J Epidemiol. 1968;87:32–33.
101. Clarke DH. Two nonfatal human infections with the virus of eastern equine encephalitis. Am J Trop Med Hyg. 1961;10:67–70.
102. Deresiewicz RL, Thaler SJ, Hsu L, et al. Clinical and neuroradiographic manifestations of eastern equine encephalitis. N Engl J Med. 1997;336:1867–1874.
103. Przelomski MM, O’Rourke E, Grady GF, et al. Eastern equine encephalitis in Massachusetts: a report of 16 cases, 1970–1984. Neurology. 1988;38:736–739.
104. Cole FE Jr. Inactivated eastern equine encephalomyelitis vaccine propagated in rolling-bottle cultures of chick embryo cells. Appl Microbiol. 1971;22:842–845.
105. Wang E, Volkova E, Adams AP, et al. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine. 2008;26:5030–5039.
106. Meyer KF, Haring CM, Howitt B. The etiology of encephalomyelitis in horses in the San Joaquin Valley. Science. 1931;74:227–228.
107. Howitt BF. Recovery of the virus of equine encephalomyelitis from the brain of a child. Science. 1938;88:455–456.
108. Calisher CH, Karabatsos N, Lazuick JS, et al. Reevaluation of the western equine encephalitis antigenic complex of alphaviruses (family Togaviridae) as determined by neutralization tests. Am J Trop Med Hyg. 1988;38:447–452.
109. Reisen WK, Chiles RE, Lothrup HD, et al. Prevalence of antibodies to mosquito-borne encephalitis viruses in residents of the Coachella Valley, California. Am J Trop Med Hyg. 1996;55:667–671.
110. Calisher CH. Medically important arboviruses of the United States and Canada. Clin Microbiol Rev. 1994;7:89–116.
111. Bigler WJ, Lassing EB, Buff EE, et al. Endemic eastern equine encephalomyelitis in Florida: a twenty-year analysis, 1955–1974. Am J Trop Med Hyg. 1976;25:884–890.
112. Arboviral infections of the central nervous system—United States, 1987. MMWR Morb Mortal Wkly Rep. 1988;37:506–508, 513–505.
113. Copps SC, Giddings LE. Transplacental transmission of western equine encephalitis. Pediatrics. 1959;24:31–33.
114. Longshore WA, Stevens IM, Hollister AC, et al. Epidemiologic observations on acute infectious encephalitis in California with special reference to the 1952 outbreak. Am J Hyg. 1956;63:69–86.
115. Schultz DR, Barthal JS, Garrett G. Western equine encephalitis with rapid onset of parkinsonism. Neurology. 1977;27:1095–1096.
116. Bia FJ, Thornton GF, Main AJ, et al. Western equine encephalitis mimicking herpes simplex encephalitis. JAMA. 1980;244:367–369.
117. Sciple GW, Ray G, LaMotte LC, et al. Western encephalitis with recovery of virus from cerebrospinal fluid. Neurology. 1967;17:169–171.
118. Gold H, Hampil B. Equine encephalomyelitis in a laboratoy technician with recovery. Ann Intern Med. 1942;16:556–569.
119. Randall R, Mills JW, Engel LL. The preparation and properties of a purified equine encephalomyelitis vaccine. J Immunol. 1947;55:41–52.
120. Barabe ND, Rayner GA, Christopher ME, et al. Single-dose, fast-acting vaccine candidate against western equine encephalitis virus completely protects mice from intranasal challenge with different strains of the virus. Vaccine. 2007;25:6271–6276.
121. Wu JQ, Barabé ND, Chau D, et al. Complete protection of mice against a lethal dose challenge of western equine encephalitis virus after immunization with an adenovirus-vectored vaccine. Vaccine. 2007;25:4368–4375.
122. Beck CE, Wyckoff RWG. Venezuelan equine encephalomyelitis. Science. 1938;88:530.
123. Calisher CH, Monath TP, Mitchell CJ, et al. Arbovirus investigations in Argentina, 1977–1980. III. Identification and characterization of viruses isolated, including new subtypes of western and Venezuelan equine encephalitis viruses and four new bunyaviruses (Las Maloyas, Resistencia, Barranqueras, and Antequera). Am J Trop Med Hyg. 1985;34:956–965.
124. Talarmin A, Trochu J, Gardon J, et al. Tonate virus infection in French Guiana: clinical aspects and seroepidemiologic study. Am J Trop Med Hyg. 2001;64:274–279.
125. Hommel D, Heraud JM, Hulin A, et al. Association of Tonate virus (subtype IIIB of the Venezuelan equine encephalitis complex) with encephalitis in a human. Clin Infect Dis. 2000;30:188–190.
126. Libraty DH, Nisalak A, Endy TP, et al. Clinical and immunological risk factors for severe disease in Japanese encephalitis. Trans R Soc Trop Med Hyg. 2002;96:173–178.
127. Brault AC, Powers AM, Weaver SC. Vector infection determinants of Venezuelan equine encephalitis virus reside within the E2 envelope glycoprotein. J Virol. 2002;76:6387–6392.
128. Weaver SC, Salas R, Rico-Hesse R, et al. Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group. Lancet. 1996;348:436–440.
129. Wang E, Barrera R, Boshell J, et al. Genetic and phenotypic changes accompanying the emergence of epizootic subtype IC Venezuelan equine encephalitis viruses from an enzootic subtype ID progenitor. J Virol. 1999;73:4266–4271.
130. Powers AM, Oberste MS, Brault AC, et al. Repeated emergence of epidemic/epizootic Venezuelan equine encephalitis from a single genotype of enzootic subtype ID virus. J Virol. 1997;71:6697–6705.
131. Rico-Hesse R, Weaver SC, de Siger J, et al. Emergence of a new epidemic/epizootic Venezuelan equine encephalitis virus in South America. Proc Natl Acad Sci U S A. 1995:92;5278–5281.
132. Weaver SC, Pfeffer M, Marriott K, et al. Genetic evidence for the origins of Venezuelan equine encephalitis virus subtype IAB outbreaks. Am J Trop Med Hyg. 1999;60:441–448.
133. Rivas F, Diaz LA, Cardenas VM, et al. Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995. J Infect Dis. 1997;175:828–832.
134. Bowen GS, Calisher CH. Virological and serological studies of Venezuelan equine encephalomyelitis in humans. J Clin Microbiol. 1976;4:22–27.
135. Bowen GS, Fashinell TR, Dean PB, et al. Clinical aspects of human Venezuelan equine encephalitis in Texas. Bull Pan Am Health Organ. 1976;10:46–57.
136. Sanchez JL, Takafuji ET, Lednar WM, et al. Venezuelan equine encephalomyelitis: report of an outbreak associated with jungle exposure. Mil Med. 1984;149:618–621.
137. Molina OM, Morales MC, Soto ID, et al. Venezuelan equine encephalitis. 1995 outbreak: clinical profile of the case with neurologic involvement. Rev Neurol. 1999;29:296–298.
138. Watts DM, Callahan J, Rossi C, et al. Venezuelan equine encephalitis febrile cases among humans in the Peruvian Amazon River region. Am J Trop Med Hyg. 1998;58:35–40.
139. Wang E, Paessler S, Aguilar PV, et al. A novel, rapid assay for detection and differentiation of serotype-specific antibodies to Venezuelan equine encephalitis complex alphaviruses. Am J Trop Med Hyg. 2005;72:805–810.
140. Berge TO, Banks IS, Tigertt WD. Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea-pig heart cells. Am J Hyg. 1961;73:209–218.
141. Hart MK, Caswell-Stephan K, Bakken R, et al. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine. 2000;18:3067–3075.
142. Fine DL, Roberts BA, Terpening SJ, et al. Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates. Vaccine. 2008;26:3497–3506.
143. Paessler S, Fayzulin RZ, Anishchenko M, et al. Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic. J Virol. 2003;77:9278–9286.
144. Paessler S, Ni H, Petrakova O, et al. Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses. J Virol. 2006;80:2784–2796.
145. Paessler S, Rijnbrand R, Stein DA, et al. Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers. Virology. 2008;376:357–370.
146. Goodchild SA, O’Brien LM, Steven J, et al. A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus. Antiviral Res. 2011;90:1–8.
147. Lumsden WH. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. II. General description and epidemiology. Trans R Soc Trop Med Hyg. 1955;49:33–57.
148. Carey DE. Chikungunya and dengue: a case of mistaken identity? J Hist Med Allied Sci. 1971;26:243–262.
149. Ross RW. The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic. J Hyg (Lond). 1956;54:177–191.
150. Spence LP, Thomas L. Application of haemagglutination and complementfixation techniques to the identification and serological classification of arthropod-borne viruses; studies on Chikungunya and Makonde viruses. Trans R Soc Trop Med Hyg. 1959;53:248–255.
151. Powers AM, Logue CH. Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol. 2007;88:2363–2377.
152. Ng LC, Hapuarachchi HC. Tracing the path of Chikungunya virus—evolution and adaptation. Infect Genet Evol. 2010;10:876–885.
153. Tsetsarkin KA, Chen R, Sherman MB, et al. Chikungunya virus: evolution and genetic determinants of emergence. Curr Opin Virol. 2011;1:310–317.
154. Pulmanausahakul R, Roytrakul S, Auewarakul P, et al. Chikungunya in Southeast Asia: understanding the emergence and finding solutions. Int J Infect Dis. 2011;15:e671–e676.
155. Renault P, Balleydier E, D’Ortenzio E, et al. Epidemiology of chikungunya infection on Reunion Island, Mayotte, and neighboring countries. Med Mal Infect. 2012;42:93–101.
156. Tsetsarkin KA, Weaver SC. Sequential adaptive mutations enhance efficient vector switching by Chikungunya virus and its epidemic emergence. PLoS Pathog. 2011;7:e1002412.
157. Rezza G, Nicoletti L, Angelini R, et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet. 2007;370:1840–1846.
158. Gould EA, Gallian P, De Lamballerie X, et al. First cases of autochthonous dengue fever and chikungunya fever in France: from bad dream to reality! Clin Microbiol Infect. 2010;16:1702–1704.
159. Lanciotti RS, Kosoy OL, Laven JJ, et al. Chikungunya virus in US travelers returning from India, 2006. Emerg Infect Dis. 2007;13:764–767.
160. Johnson DF, Druce JD, Chapman S, et al. Chikungunya virus infection in travellers to Australia. Med J Aust. 2008;188:41–43.
161. Panning M, Grywna K, van Esbroeck M, et al. Chikungunya fever in travelers returning to Europe from the Indian Ocean region, 2006. Emerg Infect Dis. 2008;14:416–422.
162. Halstead SB, Nimmannitya S, Margiotta MR. Dengue and Chikungunya virus infection in man in Thailand, 1962–1964: II. Observations on disease in outpatients. Am J Trop Med Hyg. 1969;18:972–983.
163. Burt FJ, Rolph MS, Rulli NE, et al. Chikungunya: a re-emerging virus. Lancet. 2012;379:662–671.
164. Sissoko D, Malvy D, Ezzedine K, et al. Post-epidemic chikungunya disease on Reunion island: course of rheumatic manifestations and associated factors over a 15-month period. PLoS Negl Trop Dis. 2009;3:e389.
165. Manimunda SP, Vijayachari P, Uppoor R, et al. Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging. Trans R Soc Trop Med Hyg. 2010;104:392–399.
166. Singh SS, Manimunda SP, Sugunan AP, et al. Four cases of acute flaccid paralysis associated with chikungunya virus infection. Epidemiol Infect. 2008;136:1277–1280.
167. Rampal, Sharda M, Meena H. Neurological complications in chikungunya fever. J Assoc Physicians India. 2007;55:765–769.
168. Wielanek AC, Monredon JD, Amrani ME, et al. Guillain-Barré syndrome complicating a Chikungunya virus infection. Neurology. 2007;69:2105–2107.
169. Arpino C, Curatolo P, Rezza G. Chikungunya and the nervous system: what we do and do not know. Rev Med Virol. 2009;19:121–129.
170. Economopoulou A, Dominguez M, Helynck B, et al. Atypical chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on Réunion. Epidemiol Infect. 2009;137:534–541.
171. Robin S, Ramful D, Le Seach F, et al. Neurologic manifestations of pediatric Chikungunya infection. J Child Neurol. 2008;23:1028–1035.
172. Gérardin P, Barau G, Michault A. Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the Island of La Ré union. PLoS Med. 2008;5 (3):e60.
173. Panning M, Charrel RN, Mantke OD, et al. Coordinated implementation of chikungunya virus reverse transcription-PCR. Emerg Infect Dis. 2009;15:469–471.
174. Hasebe F, Parquet MC, Pandey BD, et al. Combined detection and genotyping of Chikungunya virus by a specific reverse transcription-polymerase chain reaction. J Med Virol. 2002;67:370–374.
175. Litzba N, Schuffenecker I, Zeller H, et al. Evaluation of the first commercial chikungunya virus indirect immunofluorescence test. J Virol Methods. 2008;149:175–179.
176. Shukla J, Khan M, Tiwari M, et al. Development and evaluation of antigen capture ELISA for early clinical diagnosis of chikungunya. Diagn Microbiol Infect Dis. 2009;65:142–149.
177. Yap G, Pok KY, Lai YL, et al. Evaluation of chikungunya diagnostic assays: differences in sensitivity of serology assays in two independent outbreaks. PLoS Negl Trop Dis. 2010;4:e753.
178. de Lamballerie X, Ninove L, Charrel RN. Antiviral treatment of chikungunya virus infection. Infect Disord Drug Targets. 2009;9:101–104.
179. Moulay D, Aziz-Alaoui MA, Kwon HD. Optimal control of chikungunya disease: larvae reduction, treatment and prevention. Math Biosci Eng. 2012;9:369–392.
180. Tiwari M, Parida M, Santhosh SR, et al. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine. 2009;27:2513–2522.
181. Mallilankaraman K, Shedlock DJ, Bao H, et al. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis. 2011;5:e928.
182. Akahata W, Yang ZY, Andersen H, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med. 2010;16:334–338.
183. Wang D, Suhrbier A, Penn-Nicholson A, et al. A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine. 2011;29:2803–2809.
184. Zanotto PM, Gould EA, Gao GF, et al. Population dynamics of flaviviruses revealed by molecular phylogenies. Proc Natl Acad Sci U S A. 1996;93:548–553.
185. Gould EA, Zanotto PM, Holmes EC. The genetic evolution of flaviviruses. In: Saluzzo JF, Dodet B, eds. Factors in the Emergence of Arbovirus Diseases. Paris: Elselvier; 1997:51–63.
186. Chambers TJ, Hahn CS, Galler R, et al. Flavivirus genome organisation, expression, and replication. Annu Rev Microbiol. 1990;44:649–688.
187. Stadler K, Allison SL, Schalich J, et al. Proteolytic activation of tick-borne encephalitis virus by furin. J Virol. 1997;71:8475–8481.
188. Roehrig JT, Hunt AR, Johnson AJ, et al. Synthetic peptides derived from the deduced amino acid sequence of the E-glycoprotein of Murray Valley encephalitis virus elicit antiviral antibody. Virology. 1989;171:49–60.
189. Rey FA, Heinz FX, Mandl C, et al. The envelope glycoprotein from tick-borne encephalitis virus at 2Å resolution. Nature. 1995;375:291–298.
190. Heinz FX, Allison SL. The machinery for flavivirus fusion with host cell membranes. Curr Opin Microbiol. 2001;4:450–455.
191. Smithburn KC, Hughes TP, Burke AW, et al. A neurotropic virus isolated from the bood of a native of Uganda. Am J Trop Med Hyg. 1940;20:471–492.
192. McIntosh BM, Jupp PG, Dos Santos I, et al. Epidemics of West Nile and Sindbis viruses in South Africa with Culex (culex) univittatus Theobold as vector. S Afr J Sci. 1976;72:295–300.
193. Spigland I, Jasinska-Klingberg W, Hofsbi E, et al. Clinical and laboratory observations in an outbreak of West Nile fever in Israel. Harefua (Jerusalem). 1958;54:275–281.
194. Tsai TF, Popovici F, Carnescu C, et al. West Nile encephalitis epidemic in Southeastern Romania. Lancet. 1998;352:767–771.
195. Platonov AE, Shipulin GA, Shipulina OY, et al. Outbreak of West Nile virus infection, Volgograd Region, Russia, 1999. Emerg Infect Dis. 2001;7:128–132.
196. Chowers MY, Lang R, Nassar F, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis. 2001;7:675–678.
197. Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet. 2001;358:261–264.
198. Briese T, Jia X-Y, Huang C, et al. Indentification of a Kunjin/West Nile-like flavivirus in brains of patients with New York encephalitis. Lancet. 1999;354:1261–1262.
199. Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344:1807–1814.
200. Murray KO, Mertens E, Despres P. West Nile virus and its emergence in the United States of America. Vet Res. 2010;41:67.
201. Davis LE, DeBiasi R, Goade DE, et al. West Nile virus neuroinvasive disease. Ann Neurol. 2006;60:286–300.
202. Danis K, Papa A, Theocharopoulos G, et al. Outbreak of West Nile virus infection in Greece, 2010. Emerg Infect Dis. 2011;17:1868–1872.
203. Sirbu A, Ceianu CS, Panculescu-Gatej RI, et al. Outbreak of West Nile virus infection in humans, Romania, July to October 2010. Euro Surveill. 2011;16:pii:19762.
204. Danis K, Papa A, Papanikolaou E, et al. Ongoing outbreak of West Nile virus infection in humans, Greece, July to August 2011. Euro Surveill. 2011;16:pii:19951.
205. Taylor R, Work TH, Harlbut HS, et al. A study of the ecology of West Nile virus in Egypt. Am J Trop Med Hyg. 1956;5:579–620.
206. Mackenzie JS, Williams DT. The zoonotic flaviviruses of Southern, South-Eastern and Eastern Asia, and Australasia: the potential for emergent viruses. Zoonoses Public Health. 2009;56:338–356.
207. Lanciotti RS, Roehrig JT, Deubel V, et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science. 1999;286:2333–2337.
208. Lanciotti RS, Ebel GD, Deubel V, et al. Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East. Virology. 2002;298:96–105.
209. Beasley DW, Li L, Suderman MT, et al. Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology. 2002;296:17–23.
210. De Filette M, Ulbert S, Diamond M, et al. Recent progress in West Nile virus diagnosis and vaccination. Vet Res. 2012;43:16.
211. Papa A. West Nile virus infections in Greece: an update. Expert Rev Anti Infect Ther. 2012;10:743–750.
212. Rappole JH, Derrickson SR, Hubálek Z. Migratory birds and spread of West Nile virus in the Western Hemisphere. Emerg Infect Dis. 2000;6:319–328.
213. Centers for Disease Control and Prevention. West Nile virus activity—United States, October 10-16, 2002, and update on West Nile virus infections in recipients of blood transfusions. MMWR Morb Mortal Wkly Rep. 2002;51:929–931.
214. Goldblum N, Sterk VV, Paderski B. West Nile fever: the clinical features of the disease and the isolation of West Nile virus from the blood of nine human cases. Am J Hyg. 1954;59:89–103.
215. Asnis DS, Conetta R, Teixeira AA, et al. The West Nile virus outbreak of 1999 in New York: the Flushing Hospital experience. Clin Infect Dis. 2000;30:413–418.
216. Leis AA, Stokic DS, Polk JL, et al. A poliomyelitis-like syndrome from West Nile virus infection. N Engl J Med. 2002;347:1279–1280.
217. Misra UK, Kalita J. Movement disorders in Japanese encephalitis. J Neurol. 1997;244:299–303.
218. Cernesu C, Ruta SM, Tardei G, et al. A high number of severe neurologic clinical forms during an epidemic of West Nile virus infection. Rom J Virol. 1997;48:13–25.
219. Weiss D, Carr D, Kellachan J, et al. Clinical findings of West Nile virus infection in hospitalized patients, New York and New Jersey, 2000. Emerg Infect Dis. 2001;7:654–658.
220. Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med. 2002;137:173–179.
221. Lanciotti RS, Kerst AJ, Nasci RS, et al. Rapid detection of West Nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-PCR assay. J Clin Microbiol. 2000;38:4066–4071.
222. Dauphin G, Zientara S. West Nile virus: recent trends in diagnosis and vaccine development. Vaccine. 2007;25:5563–5576.
223. Huang C, Slater B, Rudd R, et al. First isolation of West Nile virus from a patient with encephalitis in the United States. Emerg Infect Dis. 2002;8:1367–1371.
224. Davis BS, Chang GJ, Cropp B, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol. 2001;75:4040–4047.
225. Ng T, Hathaway D, Jennings N, et al. Equine vaccine for West Nile virus. Dev Biol (Basel). 2003;114:221–227.
226. Guy B, Barrere B, Malinowski C, et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011;29:7229–7241.
227. Beasley DW. Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus. Immunotherapy. 2011;3:269–285.
228. Kaneko R, Aoki Y. Uber die Encephalitis epidemica in Japan. Ergebn d inn Med u Kinderh. 1928;34:342–456.
229. Solomon T. Japanese encephalitis. In: Gilman S, Goldstein GW, Waxman SG, eds. Neurobase. San Diego: Medlink Publishing; 2000.
230. Vaughn DW, Hoke CH. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev. 1992;14:197–221.
231. Shlim DR, Solomon T. Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin Infect Dis. 2002;35:183–188.
232. Solomon T, Dung NM, Kneen R, et al. Japanese encephalitis. J Neurol Neurosurg Psychiatry. 2000;68:405–415.
233. Chen WR, Tesh RB, Ricco-Hesse R. Genetic variation of Japanese encephalitis virus in nature. J Gen Virol. 1990;71:2915–2922.
234. Chen WR, Ricco-Hesse R, Tesh RB. A new genotype of Japanese virus from Indonesia. Am J Trop Med Hyg. 1992;47:61–69.
235. Solomon T, Ni H, Beasley DW, et al. Origin and evolution of Japanese encephalitis virus in Southeast Asia. J Virol. 2003;77:3091–3098.
236. Mohammed MAF, Galbraith SE, Radford AD, et al. Molecular phylogenetic and evolutionary analyses of Muar strain of Japanese encephalitis virus reveal it is the missing fifth genotype. Infect Genet Evol. 2011;11:855–862.
237. Li M-H, Fu S-H, Chen W-X, et al. Genotype V Japanese encephalitis virus is emerging. PLoS Negl Trop Dis. 2011;5:e1231.
238. Takhampunya R, Kim H-C, Tippayachai B, et al. Emergence of Japanese encephalitis virus genotype V in the Republic of Korea. Virol J. 2011;8:449.
239. Kumar R, Mathur A, Kumar A, et al. Clinical features and prognostic indicators of Japanese encephalitis in children in Lucknow (India). Indian J Med Res. 1990;91:321–327.
240. Zimmerman HM. The pathology of Japanese B encephalitis. Am J Pathol. 1946;22:965–991.
241. Misra UK, Kalita J. Anterior horn cells are also involved in Japanese encephalitis. Acta Neurol Scand. 1997;96:114–117.
242. Desai A, Ravi V, Guru SC, et al. Detection of autoantibodies to neural antigens in the CSF of Japanese encephalitis patients and correlation of findings with the outcome. J Neurol Sci. 1994;122:109–116.
243. Dapeng L, Jindou S, Huijun Y, et al. Prognostic factors of early sequelae and fatal outcome of Japanese encephalitis. Southeast Asian J Trop Med Public Health. 1995;26:694–698.
244. Misra UK, Kalita J, Srivastava M. Prognosis of Japanese encephalitis: a multivariate analysis. J Neurol Sci. 1998;161:143–147.
245. Solomon T, Thao LTT, Dung NM, et al. Rapid diagnosis of Japanese encephalitis by using an immunoglobulin M dot enzyme immunoassay. J Clin Microbiol. 1998;36:2030–2034.
246. Burke DS, Nisalak A, Lorsomrudee W, et al. Virus-specific antibody-producing cells in blood and cerebrospinal fluid in acute Japanese encephalitis. J Med Virol. 1985;17:283–292.
247. Ravi V, Desai A, Balaji M, et al. Development and evaluation of a rapid IgM capture ELISA (JEV-Chex) for the diagnosis of Japanese encephalitis. J Clin Virol. 2006;35:429–434.
248. Igarashi A, Tanaka M, Morita K, et al. Detection of West Nile and Japanese encephalitis viral genome sequences in cerebrospinal fluid from acute encephalitis cases in Karachi, Pakistan. Microbiol Immunol. 1994;38:827–830.
249. Harinasuta C, Wasi C, Vithanomsat S. The effect of interferon on Japanese encephalitis virus in vitro. Southeast Asian J Trop Med Public Health. 1984;15:564–568.
250. Huggins JW, Robins RK, Canonico P. Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses. Antimicrob Agents Chemother. 1984;26:476–480.
251. Saxena SK, Singh A, Mathur A. Antiviral effect of nitric oxide during Japanese encephalitis virus infection. Int J Exp Pathol. 2000;81:165–172.
252. Harinasuta C, Nimmanitya S, Titsyakorn U. The effect of interferon alpha A on two cases of Japanese encephalitis in Thailand. Southeast Asian J Trop Med Public Health. 1985;16:332–336.
253. Das S, Dutta K, Kumawat KL, et al. Abrogated inflammatory response promotes neurogenesis in a murine model of Japanese encephalitis. PLoS One. 2011;6:e17225.
254. Mishra MK, Dutta K, Saheb SK, et al. Understanding the molecular mechanism of blood-brain barrier damage in an experimental model of Japanese encephalitis: correlation with minocycline administration as a therapeutic agent. Neurochem Int. 2009;55:717–723.
255. Sebastian L, Desai A, Madhusudana SN, et al. Pentoxifylline inhibits replication of Japanese encephalitis virus: a comparative study with ribavirin. Int J Antimicrob Agents. 2009;33:168–173.
256. Lacey LA, Lacey CM. The medical importance of riceland mosquitoes and their control using alternatives to chemical insecticides. J Am Mosq Control Assoc Suppl. 1990;2:1–93.
257. Hoke CH, Nisalak A, Sangawhipa N, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med. 1988;319:608–614.
258. Takahashi H, Pool V, Tsai TF, et al. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. Vaccine. 2000;18:2963–2969.
259. McArthur MA, Holbrook MR. Japanese encephalitis vaccines. J Bioterror Biodef. 2011;S1:2.
260. Xin YY, Ming ZG, Peng GY, et al. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am J Trop Med Hyg. 1988;39:214–217.
261. Ma X, Yu YX, Wang SG. Observations on safety and serological efficacy from a large scale field trial of Japanese encephalitis vaccine. Chin J Biol. 1993;6:188–191.
262. Hennessy S, Zhengle L, Tsai TF, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case control study. Lancet. 1996;347:1583–1586.
263. Monath TP, McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002;20:1004–1018.
264. Muckenfuss RW, Armstrong C, McCordock HA. Encephalitis: studies on experimental transmission. Public Health Rep. 1933;48:1341–1343.
265. Monath TP. Epidemiology. In: Monath TP, ed. St Louis Encephalitis. Washington, DC: American Public Health Associates; 1980:239–312.
266. Okhuysen PC, Crane JK, Pappas J. St. Louis encephalitis in patients with human immunodeficiency virus infection. Clin Infect Dis. 1993;17:140–141.
267. Diaz LA, Re V, Almiron WR, et al. Genotype III Saint Louis encephalitis virus outbreak, Argentina, 2005. Emerg Infect Dis. 2006;12:1752–1754.
268. Spinsanti LI, Díaz LA, Glatstein N, et al. Human outbreak of St. Louis encephalitis detected in Argentina, 2005. J Clin Virol. 2008;42:27–33.
269. Brinker KR, Monath TP. The acute disease. In: Monath TP, ed. St. Louis Encephalitis. Washington, DC: American Public Health Associates; 1980:503–534.
270. Southern PM Jr, Smith JW, Luby JP, et al. Clinical and laboratory features of epidemic St. Louis encephalitis. Ann Intern Med. 1969;71:681–689.
271. Wasay M, Diaz-Arrastia R, Suss RA, et al. St Louis encephalitis: a review of 11 cases in a 1995 Dallas, Tex, epidemic. Arch Neurol. 2000;57:114–118.
272. Monath TP, Nystrom RR, Bailey RE, et al. Immunoglobulin M antibody capture enzyme-linked immunosorbent assay for diagnosis of St. Louis encephalitis. J Clin Microbiol. 1984:20:784–790.
273. Breinl A. Clinical pathological and experimental observations on the “mysterious disease,” a clinically abberant form of poliomyelitis. Med J Aust. 1918;1:209–229.
274. French EL. Murray Valley encephalitis: isolation and characterization of the aetiological agent. Med J Aust. 1952;1:100–103.
275. Mackenzie JS, Broom AK, Hall RA, et al. Arboviruses in the Australian region, 1990 to 1998. Commun Dis Intell. 1998;22:93–100.
276. Burrow JN, Whelan PI, Kilburn CJ, et al. Australian encephalitis in the Northern Territory: clinical and epidemiological features, 1987–1996. Aust N Z J Med. 1998;28:590–596.
277. Knox J, Cowan RU, Doyle JS, et al. Murray Valley encephalitis: a review of clinical features, diagnosis and treatment. Med J Aust. 2012;196:322–326.
278. Kienzle N, Boyes L. Murray Valley encephalitis: case report and review of neuroradiological features. Australas Radiol. 2003;47:61–63.
279. Lobigs M, Larena M, Alsharifi M, et al. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. J Virol. 2009;83:2436–2445.
280. Smorodintsev AA. Tick-borne spring-summer encephalitis. Progr Med Virol. 1958;1:210–247.
281. Süss J. Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia—an overview. Ticks Tick Borne Dis. 2011;2:2–15.
282. Dobler G, Gniel D, Petermann R, et al. Epidemiology and distribution of tick-borne encephalitis. Wien Med Wochenschr. 2012;162:230–238.
283. Kaiser R. The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98: a prospective study of 656 patients. Brain. 1999;122:2067–2078.
284. Gunther G, Haglund M, Lindquist L, et al. Tick-bone encephalitis in Sweden in relation to aseptic meningo-encephalitis of other etiology: a prospective study of clinical course and outcome. J Neurol. 1997;244:230–238.
285. Haglund M, Gunther G. Tick-borne encephalitis-pathogenesis, clinical course and long-term follow-up. Vaccine. 2003;21(suppl 1):S11–S18.
286. Hofmann H, Frisch-Niggemeyer W, and Heinz F. Rapid diagnosis of tick-borne encephalitis by means of enzyme linked immunosorbent assay. J Gen Virol. 1979;42:505–511.
287. Schultze D, Dollenmaier G, Rohner A, et al. Benefit of detecting tick-borne encephalitis viremia in the first phase of illness. J Clin Virol. 2007;38:172–175.
288. Chiba N, Osada M, Komoro K, et al. Protection against tick-borne encephalitis virus isolated in Japan by active and passive immunization. Vaccine. 1999;17:1532–1539.
289. Heinz FX, Kunz C, Fauma H. Preparation of a highly purified vaccine against tick-borne encephalitis by continuous flow zonal ultracentrifugation. J Med Virol. 1980;6:213–221.
290. Kunz C. Vaccination against TBE in Austria: the success story continues. Int J Med Microbiol. 2002;291(suppl 33):56–57.
291. Zent O, Hennig R. Post-marketing surveillance of immediate allergic reactions: polygeline-based versus polygeline-free pediatric TBE vaccine. Vaccine. 2004;23:579–584.
292. Girgsdies OE, Rosenkranz G. Tick-borne encephalitis: development of a paediatric vaccine. A controlled, randomized, double-blind and multicentre study. Vaccine. 1996;14:1421–1428.
293. Kollaritsch H, Paulke-Korinek M, Holzmann H, et al. Vaccines and vaccination against tick-borne encephalitis. Expert Rev Vaccines. 2012;11:1103–1119.
294. Rendi-Wagner P. Advances in vaccination against tick-borne encephalitis. Expert Rev Vaccines. 2008;7:589–596.
295. World Health Organization. Vaccines against tick-borne encephalitis: WHO position paper—recommendations. Vaccine. 2011;29:8769–8770.
296. Solomon T, Mallewa MJ. Dengue and other emerging flaviviruses. J Infect. 2001;42:104–115.
297. Gubler DJ, Kuno G, Wareman SH. Neurological disorders associated with dengue fever infection. In: Proceedings of the International Conference on Dengue/DHF; 1983; Kuala Lumpur, Malaysia.
298. Thisyakorn U, Thisyakorn C, Limpitikul W, et al. Dengue infection with central nervous system manifestations. Southeast Asian J Trop Med Public Health. 1999;30:504–506.
299. Kankirawatana P, Chokephaibulkit K, Puthavathana P, et al. Dengue infection presenting with central nervous system manifestation. J Child Neurol. 2000;15:544–547.
300. Solomon T, Dung NM, Vaughn DW, et al. Neurological manifestations of dengue infection. Lancet. 2000;355:1053–1059.
301. Nimmannitya S, Thisyakorn U, Hemsrichart V. Dengue haemorrhagic fever with unusual manifestations. Southeast Asian J Trop Med Pub Health. 1987;18:398–406.
302. Nimmannitya S. Clinical spectrum and management of dengue haemorrhagic fever. Trans R Soc Trop Med Hyg. 1987;18:292–297.
303. Soares CN, Faria LC, Peralta JM, et al. Dengue infection: neurological manifestations and cerebrospinal fluid (CSF) analysis. J Neurol Sci. 2006;249:19–24.
304. Puccioni-Sohler M, Soares CN, Papaiz-Alvarenga R, et al. Neurologic dengue manifestations associated with intrathecal specific immune response. Neurology. 2009;73:1413–1417.
305. Araújo FMC, Brilhante RSN, Cavalcanti LPG, et al. Detection of the dengue non-structural 1 antigen in cerebral spinal fluid samples using a commercially available enzyme-linked immunosorbent assay. J Virol Methods. 2011;177:128–131.
306. Araújo FMC, Araújo MS, Nogueira RM, et al. Central nervous system involvement in dengue: a study in fatal cases from a dengue endemic area. Neurology. 2012;78:736–742.
307. Solomon T, Barrett AD. Dengue. In: Nath A, Berger J, eds. Neurovirology. New York: Marcel Decker; 2003.
308. Varatharaj A. Encephalitis in the clinical spectrum of dengue infection. Neurol India. 2010;58:585–591.
309. Wang E, Ni H, Xu R, et al. Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J Virol. 2000;74:3227–3234.
310. Halstead SB. Global epidemiology of dengue hemorrhagic fever. Southeast Asian J Trop Med Public Health. 1990;21:636–641.
311. Medlock JM, Hansford KM, Schaffner F, et al. A review of the invasive mosquitoes in Europe: ecology, public health risks, and control options. Vector Borne Zoonotic Dis. 2012;12:435–447.
312. Adalja AA, Sell TK, Bouri N, et al. Lessons learned during dengue outbreaks in the United States, 2001–2011. Emerg Infect Dis. 2012;18:608–614.
313. Lum LC, Lam SK, Choy YS, et al. Dengue encephalitis: a true entity? Am J Trop Med Hyg. 1996;54:256–259.
314. Hommel D, Talarmin A, Deubel V, et al. Dengue encephalitis in French Guiana. Res Virol. 1998;149:235–238.
315. Chokephaibulkit K, Kankirawatana P, Apintanapong S, et al. Viral etiologies of encephalitis in Thai children. Pediatr Infect Dis J. 2001;20:216–218.
316. Pancharoen C, Thisyakorn U. Neurological manifestations in dengue patients. Southeast Asian J Trop Med Public Health. 2001;32:341–345.
317. Familusi JB, Moore DL, Fomufod AK, et al. Virus isolates from children with febrile convulsions in Nigeria. A correlation study of clinical and laboratory observations. Clin Pediatr (Phila). 1972;11:272–276.
318. George R, Liam CK, Chua CT, et al. Unusual clinical manifestations of dengue virus infection. Southeast Asian J Trop Med Public Health. 1988;19:585–590.
319. Thakare J, Walhekar B, Banerjee K. Hemorrhagic manifestations and encephalopathy in cases of dengue in India. Southeast Asian J Trop Med Public Health. 1996; 27(3):471–475.
320. Chimelli L, Hahn MD, Netto MB, et al. Dengue: neuropathological findings in 5 fatal cases from Brazil. Clin Neuropathol. 1990;9:157–162.
321. Misra UK, Kalita J, Syam UK, et al. Neurological manifestations of dengue virus infection. J Neurol Sci. 2006;244:117–122.
322. Hira HS, Kaur A, Shukla A. Acute neuromuscular weakness associated with dengue infection. J Neurosci Rural Pract. 2012;3:36–39.
323. Bethell DB, Gamble J, Pham PL, et al. Noninvasive measurement of microvascular leakage in patients with dengue hemorrhagic fever. Clin Infect Dis. 2001;32:243–253.
324. Cam BV, Fonsmark L, Hue NB, et al. Prospective case-control study of encephalopathy in children with dengue hemorrhagic fever. Am J Trop Med Hyg. 2001;65:848–851.
325. World Health Organization. Dengue Hemorrhagic Fever: Diagnosis, Treatment and Control. 2nd ed. Geneva: World Health Organization; 1997.
326. Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis. 2009;9:678–687.
327. Schmitz J, Roehrig J, Barrett A, et al. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine. 2011;29:7276–7284.
328. Laughlin CA, Morens DM, Cassetti MC, et al. Dengue research opportunities in the Americas. J Infect Dis. 2012;206:1121–1127.
329. Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine. 2012;30:4301–4306.
330. Rigau-Perez JG, Clark GG, Gubler DJ, et al. Dengue and dengue haemorrhagic fever. Lancet. 1998;352:971–977.
331. Monath TP. Epidemiology of yellow fever: current status and speculations on future trends. In: Saluzzo J-F, Dodet B, eds. Factors in the Emergence of Arbovirus Diseases. Paris: Elsevier; 1997:143–158.
332. Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res. 2002;33:330–342.
333. Nene V, Wortman JR, Lawson D, et al. Genome sequence of Aedes aegypti, a major arbovirus vector. Science. 2007;316:1718–1723.
334. Schmaljohn CS, Hooper JW. Bunyaviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2001:1581–1602.
335. Guu TS, Zheng W, Tao YJ. Bunyavirus: structure and replication. Adv Exp Med Biol. 2012;726:245–266.
336. Walter CT, Barr JN. Recent advances in the molecular and cellular biology of bunyaviruses. J Gen Virol. 2011;92:2467–2484.
337. Gavrilovskaya IN, Shepley M, Shaw R, et al. β3 integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci U S A. 1998;95:7074–7079.
338. Lozach PY, Kuhbacher A, Meier R, et al. DC-SIGN as a receptor for phleboviruses. Cell Host Microbe. 2011;10:75–88.
339. Lozach P-Y, Mancini R, Bitto D, et al. Entry of bunyaviruses into mammalian cells. Cell Host Microbe. 2010;7:488–499.
340. Hammon WM, Reeves WC. California encephalitis virus, a newly described agent. Calif Med. 1952;77:303–309.
341. Eldridge BF, Glaser C, Pedrin RE, et al. The first reported case of California encephalitis in more than 50 years. Emerg Infect Dis. 2001;7:451–452.
342. Thompson W, Kalfayan B, Anslow R. Isolation of California encephalitis group virus from a fatal human illness. Am J Epidemiol. 1965;81:245–253.
343. Erwin PC, Jones TF, Gerhardt RR, et al. La Crosse encephalitis in Eastern Tennessee: clinical, environmental, and entomological characteristics from a blinded cohort study. Am J Epidemiol. 2002;155:1060–1065.
344. Watts DM, Thompson WH, Yuill TM, et al. Overwintering of La Crosse virus in Aedes triseriatus. Am J Trop Med Hyg. 1974;23:694–700.
345. Demikhov VG, Chaitsev VG, Butenko AM, et al. California serogroup virus infections in the Ryazan region of the USSR. Am J Trop Med Hyg. 1991;45:371–376.
346. Lundstrom JO. Mosquito-borne viruses in western Europe: a review. J Vector Ecol. 1999;24:1–39.
347. Kappus KD, Monath TP, Kaminski RM, et al. Reported encephalitis associated with California serogroup virus infections in the United States, 1963–1981. Prog Clin Biol Res. 1983;123:31–41.
348. Centers for Disease Control and Prevention. West nile virus disease and other arboviral diseases—United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:510–514.
349. Elliott RM. Bunyaviruses and climate change. Clin Microbiol Infect. 2009;15:510–517.
350. Mayo D, Karabatsos N, Scarano FJ, et al. Jamestown Canyon virus: seroprevalence in Connecticut. Emerg Infect Dis. 2001;7:911–912.
351. Balkhy HH, Schreiber JR. Severe La Crosse encephalitis with significant neurologic sequelae. Pediatr Infect Dis J. 2000;19:77–80.
352. Cramblett HG, Stegmiller H, Spencer C. California encephalitis virus infections in children. Clinical and laboratory studies. JAMA. 1966;198:108–112.
353. Balfour HH Jr, Siem RA, Bauer H, et al. California arbovirus (La Crosse) infections. I. Clinical and laboratory findings in 66 children with meningoencephalitis. Pediatrics. 1973;52:680–691.
354. Grimstad PR, Shabino CL, Calisher CH, et al. A case of encephalitis in a human associated with a serologic rise to Jamestown Canyon virus. Am J Trop Med Hyg. 1982;31:1238–1244.
355. McJunkin JE, Nahata MC, De Los Reyes EC, et al. Safety and pharmacokinetics of ribavirin for the treatment of la crosse encephalitis. Pediatr Infect Dis J. 2011;30:860–865.
356. Sabin AB. Phlebotomus fever. In: Rivers TM, ed. Viral and Rickettsial Diseases of Man. Philadelphia: JB Lippincott; 1948:454–460.
357. Konstantinou GN, Papa A, Antoniadis A. Sandfly-fever outbreak in Cyprus: are phleboviruses still a health problem? Travel Med Infect Dis. 2007;5:239–242.
358. Verani P, Nicoletti L, Ciufolini MG. Antigenic and biological characterization of Toscana virus, a new Phlebotomus fever group virus isolated in Italy. Acta Virol. 1984;28:39–47.
359. Nicoletti L, Ciufolini MG, Verani P. Sandfly fever viruses in Italy. Arch Virol Suppl. 1996;11:41–47.
360. Braito A, Corbisiero R, Corradini S, et al. Toscana virus infections of the central nervous system in children: a report of 14 cases. J Pediatr. 1998;132:144–148.
361. Eitrem R, Stylianou M, Niklasson B. High prevalence rates of antibody to three sandfly fever viruses (Sicilian, Naples, and Toscana) among Cypriots. Epidemiol Infect. 1991;107:685–691.
362. Depaquit J, Grandadam M, Fouque F, et al. Arthropod-borne viruses transmitted by Phlebotomine sandflies in Europe: a review. Euro Surveill. 2010;15:19507.
363. Mendoza-Montero J, Gámez-Rueda MI, Navarro-Mari JM, et al. Infections due to sandfly fever virus serotype Toscana in Spain. Clin Infect Dis. 1998;27:434–436.
364. Nicoletti L, Verani P, Caciolli S, et al. Central nervous system involvement during infection by Phlebovirus toscana of residents in natural foci in central Italy (1977–1988). Am J Trop Med Hyg. 1991;45:429–434.
365. Schwarz TF, Gilch S, Jager G. Aseptic meningitis caused by sandfly fever virus, serotype Toscana. Clin Infect Dis. 1995;21:669–671.
366. Braito A, Ciufolini MG, Pippi L, et al. Phlebotomus-transmitted toscana virus infections of the central nervous system: a seven-year experience in Tuscany. Scand J Infect Dis. 1998;30:505–508.
367. Dionisio D, Valassina M, Ciufolini MG, et al. Encephalitis without meningitis due to sandfly fever virus serotype toscana. Clin Infect Dis. 2001;32:1241–1243.
368. Valassina M, Valentini M, Valensin PE, et al. Fast duplex one-step RT-PCR for rapid differential diagnosis of entero- or toscana virus meningitis. Diagn Microbiol Infect Dis. 2002;43:201–205.
369. Cusi MG, Savellini GG. Diagnostic tools for Toscana virus infection. Expert Rev Anti Infect Ther. 2011;9:799–805.
370. Valassina M, Cusi MG, Valensin PE. Rapid identification of Toscana virus by nested PCR during an outbreak in the Siena area of Italy. J Clin Microbiol. 1996;34:2500–2502.
371. Ciufolini MG, Fiorentini C, di Bonito P, et al. Detection of Toscana virus-specific immunoglobulins G and M by an enzyme-linked immunosorbent assay based on recombinant viral nucleoprotein. J Clin Microbiol. 1999;37:2010–2012.
372. Centers for Disease Control and Prevention. Outbreak of Rift Valley fever—Yemen, August-October 2000. MMWR Morb Mortal Wkly Rep. 2000;49:1065–1066.
373. Laughlin LW, Meegan JM, Strausbaugh LJ, et al. Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness. Trans R Soc Trop Med Hyg. 1979;73:630–633.
374. Maar SA, Swanepoel R, Gelfand M. Rift Valley fever encephalitis. A description of a case. Cent Afr J Med. 1979;25:8–11.
375. Peters CJ, Anderson GW Jr. Pathogenesis of Rift Valley fever. Contrib Epidemiol Biostat. 1981;3:21–41.
376. Bird BH, Nichol ST. Breaking the chain: Rift Valley fever virus control via livestock vaccination. Curr Opin Virol. 2012;2:315–323.
377. Rehse-Küpper B, Casals J, Rehse E, et al. Eyach—an arthropod-borne virus related to Colorado tick fever virus in the Federal Republic of Germany. Acta Virol. 1976;20:339–342.
378. Xu P, Wang Y, Zuo J, et al. New orbiviruses isolated from patients with unknown fever and encephalitis in Yunnan province. Chin J Virol. 1990;6:27–33.
379. Song L, Chen B, Zhao Z. Isolation and identification of new members of coltivirus from mosquitoes collected in China. Chin J Exp Clin Virol. 1995;9:7–10.
380. Attoui H, Billoir F, Biagini P, et al. Complete sequence determination and genetic analysis of Banna virus and Kadipiro virus: proposal for assignment to a new genus (Seadornavirus) within the family Reoviridae. J Gen Virol. 2000;81:1507–1515.
381. Attoui H, Mohd Jaafar F, Biagini P, et al. Genus Coltivirus (family Reoviridae): genomic and morphologic characterization of Old World and New World viruses. Arch Virol. 2002;147:533–561.
382. Knudson DL. Genome of Colorado tick fever virus. Virology. 1981;112:361–364.
383. Goodpasture HC, Poland JD, Francy DB, et al. Colorado tick fever: clinical, epidemiologic, and laboratory aspects of 228 cases in Colorado in 1973–1974. Ann Intern Med. 1978;88:303–310.
384. Bowen GS. Colorado tick fever. In: Monath TP, ed. The Arboviruses: Ecology and Epidemiology. Boca Raton, FL: CRC Press Inc; 1988:159–176.
385. Philipp CS, Callaway C, Chu MC, et al. Replication of Colorado tick fever virus within human hematopoietic progenitor cells. J Virol. 1993;67:2389–2395.
386. Hierholzer WJ, Barry DW. Colorado tick fever pericarditis. JAMA. 1971;217:825.
387. Spruance SL, Bailey A. Colorado tick fever. A review of 115 laboratory confirmed cases. Arch Intern Med. 1973;131:288–293.
388. Smee DF, Sidwell RW, Clark SM, et al. Inhibition of bluetongue and Colorado tick fever orbiviruses by selected antiviral substances. Antimicrob Agents Chemother. 1981;20:533–538.